

PTO/SB/29 (12/97)
Approved for use through 09/30/00. OMB 0651-0032

Approved for use through 09.0000. OMB 0651-0022

Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a vaid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. 7991-086 Total Pages 63
First Named Inventor or Application Identifier

		TRANSMITTAL	etham et al.							
	(Only for new nonprovisional applications under 37 CFR 1 53(b))	ess Mail Label No. EL 501 634 414 US							
	s	APPLICATION ELEMENTS ee MPEP chapter 600 concerning utility patent application contents	Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC 20231							
1.	X	Fee Transmittal Form Submit an original, and a duplicate for fee processing)		6. Microfiche Computer Program (Appendix)						
2.	×	Specification including Table of Contents [Total Pages _ (preferred arrangement set forth below)	31]	7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)						
		-Descriptive title of the Invention		a. ⊠ Computer Readable Copy						
		-Cross Reference to Related Applications		a. a Computer Resulable Copy						
		-Statement Regarding Fed sponsored R&D		b.						
		-Reference to Microfiche Appendix								
		-Background of the Invention		c. Statement verifying identity of above copies						
		-Brief Summary of the Invention		ACCOMPANYING APPLICATION PARTS						
		-Brief Description of the Drawings (if filed)								
		-Detailed Description of the Invention (including drawings, if filed) -Claim(s)		8. Assignment Papers (cover sheet & document(s))						
		-Abstract of the Disclosure		9. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee)						
3.	8	Drawing(s) (35 USC 113) [Total Sheets _	10]	10. □ English Translation Document (if applicable)						
4.		Oath or Declaration [Total Sheets _	2]	11. □ Information Disclosure □ Copies of IDS Statement (IDS)/PTO-1449 Citations						
	a.	3 (g cop))		12. Preliminary Amendment						
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]		13. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
		i. DELETION OF INVENTORS(S)		Small Entity						
		Signed statement attached deleting inventor(s) named in the papplication, see 37 CFR 1.63(d)(2) and 1.33 (b).	rior	Cattlified Copy of Priority Document(s) (If foreign priority is claimed)						
5.		Incorporation By Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the or declaration is supplied under Box 4b, is considered as being part of disclosure of the accompanying application and is hereby incorporate reference therein.	f the d by	16. a Other:						
17.	If a	a CONTINUING APPLICATION, check appropriate box and supply the Continuation Divisional Continuation-in-part (CIP)	e <i>requis</i> of prior a	ite information: application No: filed .						
		18. CORRESPON	DENCE	ADDRESS						
6	CL	ustomer Number or Bar Code Label (Insert Customer No. or Att	33							
VA1	4E									
nn	RE.	ss								
)T			TATE	ZIP CODE						
OU	INT	RY TELEPI	IONE	FAX						

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the armount of time you are required to complete this form should be sent to the Chie Information Officer, Petent and Trademark Office, Westington, DC 20231, DO VISEO FEED OF CONTRACT Parties (). So Petent and Trademark Office, Westington, DC 20231, DO VISEO FEED OF CONTRACT Parties (). So Petent and Trademark Office, Westington, DC 20231, DO VISEO FEED OF CONTRACT Parties (). So Petent and Trademark Office, Westington, DC 20231, DO VISEO FEED OF CONTRACT Parties (). So Petent and Trademark Office, Westington, DC 20231, DO VISEO FEED OF CONTRACT PARTIES ().

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW 1155 Avenue of the Americas New York, N.Y. 10036-2711 (212) 790-9090

ATTORNEY DOCKET NO. 7991-086

Date: October 10, 2000

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Applicant(s): Beetham et al.

Sir:

The following utility patent application is enclosed for filing:

Title of Invention: NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

Executed on: unexecuted

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE			
Total Claims	38	-20	-20 18		\$	324.00		
Independent	5	-3	2	\$80.00 each	\$	160.00		
	Minimum Fee							
	S	270.00						
	Total							
	- s	0.00						
	s	1.464.00						

This application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and U.S. Provisional Application No. 60/173,564, filed December 30, 1999.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is

enclosed.

126 NO 40 203 29 258

homas E. Friebel PENNIE & EDMONDS ILP

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

TABLE OF CONTENTS

5	1.	FIEL	D OF THE INVENTION	. 1
	2.	BACI	KGROUND TO THE INVENTION	
		2.1	PHOSPHONOMETHYLGLYCINE HERBICIDES	
10		2.2	RECOMBINAGENIC OLIGONUCLEOBASES	. 3
	3.	SUM	MARY OF THE INVENTION	. 4
		3.1	DEFINITIONS	. 5
15	4.	BRIE	F DESCRIPTION OF THE FIGURES	. 7
	5.	DETA	AILED DESCRIPTION OF THE INVENTION	. 8
		5.1	RECOMBINAGENIC OLIGONUCLEOBASES	. 9
		5.2	THE LOCATION AND TYPE OF MUTATION	
20			INTRODUCED INTO THE EPSPS GENE	14
20		5.3	THE DELIVERY OF RECOMBINAGENIC	
			OLIGONUCLEOBASES INTO PLANT CELLS	18
			5.3.1 MICROCARRIERS AND MICROFIBERS	18
			5.3.2 PROTOPLAST ELECTROPORATION	19
25			5.3.3 WHISKERS AND MICROINJECTION	20
		5.4	SELECTION OF GLYPHOSATE RESISTANT PLANTS	20
	6. EX	AMPLI	E	20
		6.1	MATERIAL AND METHODS	20
30			6.1.1 ISOLATION OF ARABIDOPSIS THALIANA	
30			EPSPS cDNA	20
			6.1.2 PREPARATION OF THE EXPRESSION VECTOR	21
			6.1.3 CLONING OF THE ARABIDOPSIS EPSPS	
			GENE INTO BACTERIAL EXPRESSION VECTOR	21
35			6.1.4 NOVEL POINT MUTATIONS IN THE EPSPS GENE	21
رر			6.1.5 GLVPHOSATE DESIGNANCE ASSAUS	22

]	<u>Page</u>	
5	6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES		22
	6.2 RESULTS		23
	WE CLAIM:		24
10	ABSTRACT		29

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

The present application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and to U.S. Provisional Application No. 60/173,564, filed December 30, 1999, the disclosures of each of which are incorporated by reference herein in their entirety.

1. FIELD OF THE INVENTION

The present invention relates to the production of a non-transgenic plant

10 resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate.

The present invention also relates to the use of a recombinagenic oligonucleobase to make a
desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding
for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which
substantially maintains the catalytic activity of the wild-type protein, allows for increased
15 resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family,
and allows for the substantially normal growth or development of the plant, its organs,
tissues or cells as compared to the wild-type plant irrespective of the presence or absence of
the herbicide. The present invention also relates to a non-transgenic plant cell in which the
EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a
20 plant resulting from a cross using a regenerated non-transgenic plant having a mutated
EPSPS gene.

2. BACKGROUND TO THE INVENTION

2.1 PHOSPHONOMETHYLGLYCINE HERBICIDES

- 25 Herbicide-tolerant plants may reduce the need for tillage to control weeds thereby effectively reducing soil erosion. One herbicide which is the subject of much investigation in this regard is N-phosphonomethylglycine, commonly referred to as glyphosate. Glyphosate inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, hormones and vitamins. Specifically,
- 30 glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme
 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS). For purposes of the present invention, the term "glyphosate" includes any herbicidally effective form of N-phosphonomethylglycine (including any salt thereof), other
- 35 forms which result in the production of the glyphosate anion in plants and any other herbicides of the phosphonomethlyglycine family.

Tolerance of plants to glyphosate can be increased by introducing a mutant EPSPS gene having an alteration in the EPSPS amino acid coding sequence into the genome of the plant. Examples of some of the mutations in the EPSPS gene for inducing glyphosate tolerance are described in the following patents: U.S. Patent No. 5,310,667; U.S.

- 5 Patent No. 5,866,775; U.S. Patent No. 5,312,910; U.S. Patent No. 5,145,783. These proposed mutations typically have a higher K, for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate-tolerant phenotype, but these variants are also characterized by a high K_m for PEP which makes the enzyme kinetically less efficient (Kishore et al., 1984, Arn. Rev. Biochem. 57:627-663; Schulz et al., 1984, Arch. Microbiol.
- 10 137: 121-123; Sost et al., 1984, FEBS Lett. 173: 238-241; Kishore et al., 1986, Fed. Proc. 45: 1506; Sost and Amrhein, 1990, Arch. Biochem. Biophys. 282: 433-436). Many mutations of the EPSPS gene are chosen so as to produce an EPSPS enzyme that is resistant to herbicides, but unfortunately, the EPSPS enzyme produced by the mutated EPSPS gene has a significantly lower enzymatic activity than the wild-type EPSPS. For example, the
- 15 apparent K_m for PEP and the apparent K, for glyphosate for the wild-type EPSPS from E. coli are 10 μM and 0.5 μM, while for a glyphosate-tolerant isolate having a single amino acid substitution of alanine for glycine at position 96, these values are 220 μM and 4.0 mM, respectively. A number of glyphosate-tolerant EPSPS genes have been constructed by mutagenesis. Again, the glyphosate-tolerant EPSPS had lower catalytic efficiency (V_{max})
- 20 /K_m), as shown by an increase in the K_m for PEP, and a slight reduction of the V_{max} of the wild-type plant enzyme (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

Since the kinetic constants of the variant enzymes are impaired with respect to PEP, it has been proposed that high levels of overproduction of the variant enzyme, 40-80 fold, would be required to maintain normal catalytic activity in plants in the presence 25 of glyphosate (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663). It has been shown that glyphosate-tolerant plants can be produced by inserting into the genome of the plant the capacity to produce a higher level of EPSP synthase in the chloroplast of the cell (Shah et al., 1986, Science 233, 478-481), which enzyme is preferably glyphosate-tolerant (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

The introduction of the exogenous mutant EPSPS genes into plant is well documented. For example, according to U.S. Patent No. 4,545,060, to increase a plant's resistance to glyphosate, a gene coding for an EPSPS variant having at least one mutation that renders the enzyme more resistant to its competitive inhibitor, *i.e.*, glyphosate, is introduced into the plant genome. However, many complications and problems are associated with these examples. Many such mutations result in low expression of the mutated EPSPS gene product or result in an EPSPS gene product with significantly lower

enzymatic activity as compared to wild type. The low expression or low enzymatic activity of the mutated enzyme results in abnormally low levels of growth and development of the plant.

While such variants in the EPSP synthases have proved useful in obtaining transgenic plants tolerant to glyphosate, it would be increasingly beneficial to obtain a variant EPSPS gene product that is highly glyphosate-tolerant but still kinetically efficient, such that improved tolerance can be obtained with a wild-type expression level.

2.2 RECOMBINAGENIC OLIGONUCLEOBASES

Recombinagenic oligonucleobases and their use to effect genetic changes in 10 eukaryotic cells are described in United States patent No. 5,565,350 to Kmiec (Kmiec I). Kmiec I teaches a method for introducing specific genetic alterations into a target gene. Kmiec I discloses, inter alia, recombinagenic oligonucleobases having two strands, in which a first strand contains two segments of at least 8 RNA-like nucleotides that are 15 separated by a third segment of from 4 to about 50 DNA-like nucleotides, termed an "interposed DNA segment." The nucleotides of the first strand are base paired to DNA-like nucleotides of a second strand. The first and second strands are additionally linked by a segment of single stranded nucleotides so that the first and second strands are parts of a single oligonucleotide chain. Kmiec I further teaches a method for introducing specific 20 genetic alterations into a target gene. According to Kmiec I, the sequences of the RNA segments are selected to be homologous, i.e., identical, to the sequence of a first and a second fragment of the target gene. The sequence of the interposed DNA segment is homologous with the sequence of the target gene between the first and second fragment except for a region of difference, termed the "heterologous region." The heterologous 25 region can effect an insertion or deletion, or can contain one or more bases that are mismatched with the sequence of target gene so as to effect a substitution. According to Kmiec I, the sequence of the target gene is altered as directed by the heterologous region, such that the target gene becomes homologous with the sequence of the recombinagenic oligonucleobase. Kmiec I specifically teaches that ribose and 2'-O-methylribose, i.e., 2'-

30 methoxyribose, containing nucleotides can be used in recombinagenic oligonucleobases and that naturally-occurring deoxyribose-containing nucleotides can be used as DNA-like nucleotides.

U.S. Patent No. 5,731,181 to Kmiec (Kmiec II) specifically disclose the use of recombinagenic oligonucleobases to effect genetic changes in plant cells and discloses further examples of analogs and derivatives of RNA-like and DNA-like nucleotides that can be used to effect genetic changes in specific target genes. Other patents discussing the use

of recombinagenic oligonucleobases include: U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

5 Recombinagenic oligonucleobases include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in Kmiec II and other molecules taught in the above-noted patents and patent publications.

Citation or identification of any reference in Section 2, or any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having one or more mutations in the EPSPS gene, which plant has increased resistance or tolerance to a member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, e.g., glyphosate, wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety be reference herein:

30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or

35 gymnospermous plant, including any woody plant species that grows as a tree or shrub, any
herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lilv, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers [10] (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds

15 in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds,
the method comprising application to the field of a herbicide to which the said plants have
been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, e.g., 20 glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

3.1 DEFINITIONS

The invention is to be understood in accordance with the following

25 definitions.

An oligonucleobase is a polymer of nucleobases, which polymer can hybridize by Watson-Crick base pairing to a DNA having the complementary sequence.

Nucleobases comprise a base, which is a purine, pyrimidine, or a derivative or analog thereof. Nucleobases include peptide nucleobases, the subunits of peptide nucleos a acids, and morpholine nucleobases as well as nucleosides and nucleotides. Nucleosides are nucleobases that contain a pentosefuranosyl moiety, e.g., an optionally substituted riboside or 2'-deoxyriboside. Nucleosides can be linked by one of several linkage moieties, which may or may not contain a phosphorus. Nucleosides that are linked by unsubstituted phosphodiester linkages are termed nucleotides.

35 An oligonucleobase chain has a single 5' and 3' terminus, which are the ultimate nucleobases of the polymer. A particular oligonucleobase chain can contain nucleobases of all types. An oligonucleobase compound is a compound comprising one or more oligonucleobase chains that are complementary and hybridized by Watson-Crick base pairing. Nucleobases are either deoxyribo-type or ribo-type. Ribo-type nucleobases are pentosefuranosyl containing nucleobases wherein the 2' carbon is a methylene substituted with a hydroxyl, alkyloxy or halogen. Deoxyribo-type nucleobases are nucleobases other than ribo-type nucleobases and include all nucleobases that do not contain a pentosefuranosyl moiety.

An oligonucleobase strand generically includes both oligonucleobase chains and segments or regions of oligonucleobase chains. An oligonucleobase strand has a 3' end 10 and a 5' end. When a oligonucleobase strand is coextensive with a chain, the 3' and 5' ends of the strand are also 3' and 5' termini of the chain.

According to the present invention, substantially normal growth of a plant, plant organ, plant tissue or plant cell is defined as a growth rate or rate of cell division of the plant, plant organ, plant tissue, or plant cell that is at least 35%, at least 50%, at least 60%, or at least 75% of the growth rate or rate of cell division in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention, substantially normal development of a plant, plant organ, plant tissue or plant cell is defined as the occurrence of one or more developmental events in the plant, plant organ, plant tissue or plant cell that are substantially the same as those occurring in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention plant organs include, but are not limited to, leaves, stems, roots, vegetative buds, floral buds, meristems, embryos, cotyledons, endosperm, sepals, petals, pistils, carpels, stamens, anthers, microspores, pollen, pollen 25 tubes, ovules, ovaries and fruits, or sections, slices or discs taken therefrom. Plant tissues include, but are not limited to, callus tissues, ground tissues, vascular tissues, storage tissues, meristematic tissues, leaf tissues, shoot tissues, root tissues, gall tissues, plant tumor tissues, and reproductive tissues. Plant cells include, but are not limited to, isolated cells with cell walls, variously sized aggregates thereof, and protoplasts.

Plants are substantially "tolerant" to glyphosate when they are subjected to it and provide a dose/response curve which is shifted to the right when compared with that provided by similarly subjected non-tolerant like plant. Such dose/response curves have "dose" plotted on the X-axis and "percentage kill", "herbicidal effect", etc., plotted on the y-axis. Tolerant plants will require more herbicide than non-tolerant like plants in order to produce a given herbicidal effect. Plants which are substantially "resistant" to the glyphosate exhibit few, if any, necrotic, lytic, chlorotic or other lesions, when subjected to

glyphosate at concentrations and rates which are typically employed by the agrochemical community to kill weeds in the field. Plants which are resistant to a herbicide are also tolerant of the herbicide. The terms "resistant" and "tolerant" are to be construed as "tolerant and/or resistant" within the context of the present application.

5

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is the DNA sequence of *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1). The bold underlined nucleotide residues are the targeted residues.

FIG. 1B is the amino acid sequence of Arabidopsis thaliana EPSPS protein 10 (SEQ ID NO:2). The bold and underlined amino acid residues are the targeted residues.

FIG. 2 is a list of the *Arabidopsis thaliana* wild-type and mutant EPSPS nucleotide and amino acid sequences in the region of amino acid position 173 to 183; wild-type nucleotide sequence (SEQ ID NO:1) and wild-type amino acid sequence (SEQ ID NO:2), mutant A₁₇₇ nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4); mutant I₁₇₈ nucleotide sequence (SEQ ID NO:5) and amino acid sequence (SEQ ID NO:6); mutant A₁₇₇I₁₇₈ nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8); mutant I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10); mutant A₁₇₇I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12); mutant A₁₇₇I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:13) and amino acid sequence (SEQ ID NO:14); mutant V₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16); mutant L₁₇₈S₁₈₂nucleotide sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18); mutant A₁₇₇V₁₇₈ nucleotide sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇C₁₈₂ nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇C₁₈₂ nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇C₁₈₂

25 FIG. 3A-C is an alignment of the DNA of Arabidopsis thaliana EPSPS gene performed by DNAStar (LaserGene), (SEQ ID NO:1) with the nucleotide sequences of Brassica napus (SEQ ID NO:23); Petunia hybrida (SEQ ID NO:24); and Zea mays (SEQ ID NO:25) EPSPS gene. The sequences are aligned using J. Hein method with weighted residue weight table.

30

FIG. 4 is an alignment of the *Arabidopsis thaliana* EPSPS amino acid sequence (SEQ ID NO:2) with the *Brassica napus* (SEQ ID NO:26); *Petunia hybrida* (SEQ ID NO:27); and *Zea mays* (SEQ ID NO:28) EPSPS amino acid sequences. The sequences are aligned using J. Hein method with weighted residue weight table.

35 FIG. 5 is a list of the mutagenesis primers used, with the targeted codons in bold characters (mutant primer A₁₇₇ (SEQ ID NO:29); mutant primer I₁₇₈ (SEQ ID NO:30);

mutant primer $A_{177}I_{178}$ (SEQ ID NO:31); mutant primer $I_{178}S_{182}$ (SEQ ID NO:32); mutant primer $A_{177}S_{182}$ (SEQ ID NO:33); mutant primer $A_{177}I_{178}S_{182}$ (SEQ ID NO:35); mutant primer $V_{177}S_{182}$ (SEQ ID NO:35); mutant primer $V_{177}S_{182}$ (SEQ ID NO:36); mutant primer $A_{177}V_{178}$ (SEQ ID NO:37); and mutant primer $A_{177}V_{178}$ (SEQ ID NO:38)).

FIG. 6 is the growth measured by optical density at 600 nm of *Arabidopsis* clones in the presence (+) and absence (-) of 17 mM glyphosate.

FIG. 7 (top panel) is a western blot showing the expression of His-tagged Bacillus, Arabidopsis wild type (WT) and mutant (AS) EPSPS proteins isolated from cell lysates (L) and eluates (E). Untransformed Salmonella as a negative control shows no 10 EPSPS expression. The bottom panel is a silver-stained duplicate gel.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having a mutation in the EPSPS gene, which plant has increased resistance or tolerance to a 15 member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, e.g., glyphosate, wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety be reference herein:

30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865: WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or

gymnospermous plant, including any woody plant species that grows as a tree or shrub, any
herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers 10 (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds
in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds,
the method comprising application to the field of a herbicide to which the said plants have
been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, e.g.,
20 glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

5.1 RECOMBINAGENIC OLIGONUCLEOBASES

The invention can be practiced with recombinagenic oligonucleobases

25 having the conformations and chemistries described in United States patent No. 5,565,350

to Kmiec (Kmiec I) and U.S. patent No. 5,731,181 (Kmiec II) gene, which are hereby
incorporated by reference. Kmiec I teaches a method for introducing specific genetic
alterations into a target gene. The recombinagenic oligonucleobases in Kmiec I and/or
Kmiec II contain two complementary strands, one of which contains at least one segment of
30 RNA-type nucleotides (an "RNA segment") that are base paired to DNA-type nucleotides
of the other strand.

Kmiec II discloses that purine and pyrimidine base-containing nonnucleotides can be substituted for nucleotides. U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789, which are each hereby incorporated in their entirety, disclose additional recombinagenic molecules that can be used for the present invention. The term "recombinagenic oligonucleobase" is used herein to denote the molecules that can be used in the methods of the present invention and include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in Kmiec II, single stranded oligodeoxynucleotides and other recombinagenic molecules taught in the above noted patents and patent publications.

In one embodiment, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide in which the RNA-type nucleotides of the mixed duplex oligonucleotide are made RNase resistant by replacing the 2'-hydroxyl with a fluoro, chloro or bromo 10 functionality or by placing a substituent on the 2'-O. Suitable substituents include the substituents taught by the Kmiec II. Alternative substituents include the substituents taught by U.S. Patent No. 5,334,711 (Sproat) and the substituents taught by patent publications EP 629 387 and EP 679 657 (collectively, the Martin Applications), which are hereby incorporated by reference. As used herein, a 2'-fluoro, chloro or bromo derivative of a 15 ribonucleotide or a ribonucleotide having a 2'-OH substituted with a substituent described in the Martin Applications or Sproat is termed a "2'-Substituted Ribonucleotide." As used herein the term "RNA-type nucleotide" means a 2'-hydroxyl or 2'-Substituted Nucleotide that is linked to other nucleotides of a mixed duplex oligonucleotide by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II. 20 As used herein the term "deoxyribo-type nucleotide" means a nucleotide having a 2'-H, which can be linked to other nucleotides of a MDON by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.

In a particular embodiment of the present invention, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide that is linked solely by unsubstituted 25 phosphodiester bonds. In alternative embodiments, the linkage is by substituted phosphodiesters, phosphodiester derivatives and non-phosphorus-based linkages as taught by Kmiec II. In yet another embodiment, each RNA-type nucleotide in the mixed duplex oligonucleotide is a 2'-Substituted Nucleotide. Particular preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-propyloxy, 2'-allyloxy, 2'-allyloxy, 2'-hydroxylethyloxy, 2'-methoxyethyloxy, 2'-fluoropropyloxy aubstituted ribonucleotides. More preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-methoxyethyloxy, and 2'-allyloxy substituted nucleotides. In another embodiment the mixed duplex oligonucleotide is linked by unsubstituted phosphodiester bonds.

35 Although mixed duplex oligonucleotide having only a single type of 2'substituted RNA-type nucleotide are more conveniently synthesized, the methods of the

invention can be practiced with mixed duplex oligonucleotides having two or more types of RNA-type nucleotides. The function of an RNA segment may not be affected by an interruption caused by the introduction of a deoxynucleotide between two RNA-type trinucleotides, accordingly, the term RNA segment encompasses such an "interrupted RNA segment." An uninterrupted RNA segment is termed a contiguous RNA segment. In an alternative embodiment an RNA segment can contain alternating RNase-resistant and unsubstituted 2'-OH nucleotides. The mixed duplex oligonucleotides preferably have fewer than 100 nucleotides and more preferably fewer than 85 nucleotides, but more than 50 nucleotides. The first and second strands are Watson-Crick base paired. In one 10 embodiment the strands of the mixed duplex oligonucleotide are covalently bonded by a linker, such as a single stranded hexa, penta or tetranucleotide so that the first and second strands are segments of a single oligonucleotide chain having a single 3' and a single 5' end. The 3' and 5' ends can be protected by the addition of a "hairpin cap" whereby the 3' and 5' terminal nucleotides are Watson-Crick paired to adjacent nucleotides. A second hairpin cap 15 can, additionally, be placed at the junction between the first and second strands distant from the 3' and 5' ends, so that the Watson-Crick pairing between the first and second strands is stabilized.

The first and second strands contain two regions that are homologous with two fragments of the target EPSPS gene, i.e., have the same sequence as the target gene. A 20 homologous region contains the nucleotides of an RNA segment and may contain one or more DNA-type nucleotides of connecting DNA segment and may also contain DNA-type nucleotides that are not within the intervening DNA segment. The two regions of homology are separated by, and each is adjacent to, a region having a sequence that differs from the sequence of the target gene, termed a "heterologous region." The heterologous 25 region can contain one, two or three mismatched nucleotides. The mismatched nucleotides can be contiguous or alternatively can be separated by one or two nucleotides that are homologous with the target gene. Alternatively, the heterologous region can also contain an insertion or one, two, three or of five or fewer nucleotides. Alternatively, the sequence of the mixed duplex oligonucleotide may differ from the sequence of the target gene only by 30 the deletion of one, two, three, or five or fewer nucleotides from the mixed duplex oligonucleotide. The length and position of the heterologous region is, in this case, deemed to be the length of the deletion, even though no nucleotides of the mixed duplex oligonucleotide are within the heterologous region. The distance between the fragments of the target gene that are complementary to the two homologous regions is identically the 35 length of the heterologous region when a substitution or substitutions is intended. When the heterologous region contains an insertion, the homologous regions are thereby separated in

bases.

35 gene.

the mixed duplex oligonucleotide farther than their complementary homologous fragments are in the gene, and the converse is applicable when the heterologous region encodes a deletion

The RNA segments of the mixed duplex oligonucleotides are each a part of a 5 homologous region, *i.e.*, a region that is identical in sequence to a fragment of the target gene, which segments together preferably contain at least 13 RNA-type nucleotides and preferably from 16 to 25 RNA-type nucleotides or yet more preferably 18-22 RNA-type nucleotides or most preferably 20 nucleotides. In one embodiment, RNA segments of the homology regions are separated by and adjacent to, *i.e.*, "connected by" an intervening 10 DNA segment. In one embodiment, each nucleotide of the heterologous region is a nucleotide of the intervening DNA segment. An intervening DNA segment that contains

the heterologous region of a mixed duplex oligonucleotide is termed a "mutator segment."

The change to be introduced into the target EPSPS gene is encoded by the heterologous region. The change to be introduced into the EPSPS gene may be a change in 15 one or more bases of the EPSPS gene sequence or the addition or deletion of one or more

In another embodiment of the present invention, the recombinagenic

oligonucleobase is a single stranded oligodeoxynucleotide mutational vector or SSOMV, which is disclosed in International Patent Application PCT/US00/23457, which is 20 incorporated by reference in its entirety. The sequence of the SSOMV is based on the same principles as the mutational vectors described in U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789. The sequence of the SSOMV contains two regions that are homologous with the target sequence separated by a region that contains the desired genetic alteration termed the mutator region. The mutator region can have a sequence that is the same length as the sequence. Such a mutator region can cause a substitution. Alternatively, the homologous regions in the SSOMV can be contiguous to each other, while the regions in the 30 target gene having the same sequence are separated by one, two or more nucleotides. Such a SSOMV causes a deletion from the target gene of the nucleotides that are absent from the SSOMV. Lastly, the sequence of the target gene that is identical to the homologous

regions may be adjacent in the target gene but separated by one two or more nucleotides in the sequence of the SSOMV. Such an SSOMV causes an insertion in the sequence of target The nucleotides of the SSOMV are deoxyribonucleotides that are linked by unmodified phosphodiester bonds except that the 3' terminal and/or 5' terminal internucleotide linkage or alternatively the two 3' terminal and/or 5' terminal internucleotide linkages can be a phosphorothioate or phosphoamidate. As used herein an internucleotide linkage is the linkage between nucleotides of the SSOMV and does not include the linkage between the 3' end nucleotide or 5' end nucleotide and a blocking substituent, see *supra*. In a specific embodiment the length of the SSOMV is between 21 and 55 deoxynucleotides and the lengths of the homology regions are, accordingly, a total length of at least 20 deoxynucleotides and at least two homology regions should each have lengths of at least 8 10 deoxynucleotides

The SSOMV can be designed to be complementary to either the coding or the non-coding strand of the target gene. When the desired mutation is a substitution of a single base, it is preferred that both the mutator nucleotide be a pyrimidine. To the extent that is consistent with achieving the desired functional result it is preferred that both the mutator nucleotide and the targeted nucleotide in the complementary strand be pyrimidines. Particularly preferred are SSOMV that encode transversion mutations, i.e., a C or T mutator nucleotide is mismatched, respectively, with a C or T nucleotide in the complementary strand

In addition to the oligodeoxynucleotide the SSOMV can contain a 5'

20 blocking substituent that is attached to the 5' terminal carbons through a linker. The
chemistry of the linker is not critical other than its length, which should preferably be at
least 6 atoms long and that the linker should be flexible. A variety of non-toxic substituents
such as biotin, cholesterol or other steroids or a non-intercalating cationic fluorescent dye
can be used. Particularly preferred as reagents to make SSOMV are the reagents sold as
25 Cy3TM and Cy5TM by Glen Research, Sterling VA, which are blocked phosphoroamidites
that upon incorporation into an oligonucleotide yield 3,3,3',3'-tetramethyl N,N'-isopropyl
substituted indomonocarbocyanine and indodicarbocyanine dyes, respectively. Cy3 is the
most preferred. When the indocarbocyanine is N-oxyalkyl substituted it can be
conveniently linked to the 5' terminal of the oligodeoxynucleotide through as a
30 phosphodicster with a 5' terminal phosphate. The chemistry of the dye linker between the

go phosphodiester with a 5 terminal phosphate. The chemistry of the dye inker between the dye and the oligodeoxynucleotide is not critical and is chosen for synthetic convenience. When the commercially available Cy3 phosphoramidite is used as directed the resulting 5' modification consists of a blocking substituent and linker together which are a N-hydroxypropyl, N'-phosphatidylpropyl 3,3,3',3'-tetramethyl indomonocarbocyanine.

35 In the preferred embodiment the indocarbocyanine dye is tetra substituted at the 3 and 3' positions of the indole rings. Without limitation as to theory these substitutions

15

20

prevent the dye from being an intercalating dye. The identity of the substituents at these positions are not critical. The SSOMV can in addition have a 3' blocking substituent. Again the chemistry of the 3' blocking substituent is not critical.

5.2 THE LOCATION AND TYPE OF MUTATION INTRODUCED INTO THE EPSPS GENE

In one embodiment of the present invention, the Arabidopsis thaliana

EPSPS gene (see Figure 1A) and corresponding EPSPS enzyme (see Figure 1B) comprises
a mutation at one or more amino acid residues selected from the group consisting of Leu₁₇₃,

Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈, or at an analogous
position in an EPSPS paralog, and the mutation results in one or more of the following
amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ Phe
- (ii) Gly122 Ala or Ile
- (iii) Thr179 Ile or Val or Leu
- (iv) Ala₁₇₀ Gly
- (v) Met₁₈₀ Cys
- (vi) Arg₁₈₁ Leu or Ser
- (vii) Pro187 Leu or Ser
- (viii) Serge -Asp
- (ix) Ser₂₅₅ -Ala
- (x) Leu₁₀₈ -Lys.

In another embodiment of the present invention, within the EPSPS gene product, the amino acid residue to be changed is Leu within the contiguous sequence Leu
25 Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg

(SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to

35 Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the

contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

Alternatively, and/or additionally, the mutation may result in the replacement of any amino acid at positions corresponding to 256, 284-288 and 353-356 with respect to the EPSPS protein depicted in Figure 1B (SEQ ID NO. 2).

In specific embodiments of the present invention, the EPSPS gene is mutated at amino acid position 177 in which Gly is replaced by Ala. Another specific embodiment 10 is the substitution of Thr at amino acid position 178 by Ile. A further specific embodiment comprises a mutation at amino acid position 177 in which Gly is replaced by Ala, plus the additional substitution of Thr at amino acid position 178 by Ile. Other specific embodiments of the present invention are directed to mutations at amino acid position 178, in which Thr is replaced by Ile, plus the additional mutation at position 182, in which Pro is 15 replaced by Ser. Other embodiments include the substitution of Gly at amino acid position 177 by Ala, plus the additional mutation at amino acid position 182, in which Pro is substituted by Ser. Other mutated EPSPS sequences comprise the substitution of Gly at position 177 by Ala, plus the substitution at position 178, in which Thr is replaced by Ile, plus the additional substitution of Pro at amino acid position 182 by Ser. Another 20 embodiment is the substitution of Thr at amino acid position 178 by Val and the additional mutation at amino acid position 182, in which Pro is replaced by Ser. A further specific embodiment includes the substitution of Thr at position 178 by Leu, plus the mutation at amino acid position 182, in which Pro is replaced by Ser. A further embodiment includes, the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the 25 substitution of Thr at position 178 by Val. The invention also embodies the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the replacement of Thr at amino acid position 178 by Leu (see Figure 2).

The foregoing mutations in the EPSPS gene were described using the
Arabidopsis thaliana EPSPS gene (SEQ ID NO:1) and protein (SEQ ID NO:2). The
30 present invention also encompasses mutant EPSPS genes of other species (paralogs).
However, due to variations in the EPSPS genes of different species, the number of the
amino acid residue to be changed in one species may be different in another species.
Nevertheless, the analogous position is readily identified by one of skill in the art by
sequence homology. For example, Figure 3A-C shows the aligned nucleotide sequences
35 and Figure 4 shows the aligned amino acid sequences of four paralogs of the EPSPS gene,
Arabidopsis thaliana, Zea mays, Petunia hybrida, and Brassica napus. Thus, the analogous

positions in Zea mays are Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂. Thus, the Zea mays EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₉₇ Phe
- (ii) Gly₁₀₁ Ala or Ile

5

- (iii) Thr₁₀₂ Ile or Val or Leu
- (iv) Ala₁₀₃ Gly
- (v) Met₁₀₄ Cys
- (vi) Arg_{10s} Leu or Ser
- 10 (vii) Pro₁₀₆ Leu or Ser
 - (viii) Ser23 -Asp
 - (ix) Ser₁₇₀ -Ala
 - (x) Leu₁₂₂ -Lvs.

In another embodiment of the present invention, within the Zea mays EPSPS

- 15 gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the
- 20 amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro
- 25 within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly
- 30 (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In Brassica napus, the analogous amino acid positions are Leu_{169} , Gly_{173} , Thr_{174} , Ala_{175} , Met_{176} , Arg_{179} , Pro_{178} , Ser_{94} , Ser_{251} and Leu_{194} . Thus, the Brassica napus EPSPS amino acid sequence is mutated at one or more of the following amino acid

- 35 positions and results in one or more of the following substitutions:
 - (i) Leu₁₆₉ Phe

- (ii) Gly₁₇₃ Ala or Ile
- (iii) Thr₁₇₄ Ile or Val or Leu
- (iv) Ala₁₇₅ Gly
- (v) Met₁₇₆ Cys
- (vi) Arg₁₇₇ Leu or Ser
- (vii) Pro₁₇₈ Leu or Ser
- (viii) Ser₉₄ -Asp

- (ix) Ser251 -Ala
- (x) Leu₁₉₄ -Lys

In another embodiment of the present invention, within the *Brassica napus*EPSPS gene product the amino acid residue to be changed is Leu within the contiguous
sequence Leu-Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid
residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID
NO:30) and is changed to Ala or IIe; or the amino acid to be changed is Thr within the

- 15 contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-
- 20 Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the
- 25 amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In Petunia hybrida the analogous positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅,

Met₁₇₆, Arg₁₇₇, Pro₁₇₃, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the Petunia hybrida EPSPS amino acid
30 sequence is mutated at one or more of the following amino acid positions and results in one
or more of the following substitutions:

- (i) Leu₁₆₉ Phe
- (ii) Gly₁₇₃ Ala or Ile
- (iii) Thr₁₇₄ Ile or Val or Leu
- 35 (iv) Ala₁₇₅ Gly
 - (v) Met₁₇₆ Cys

30

- (vi) Arg₁₇₇ Leu or Ser
- (vii) Pro₁₇₈ Leu or Ser
- (viii) Seroa -Asp
- (ix) Ser₂₅₁ -Ala
- 5 (x) Leu₁₉₄-Lys

In another embodiment of the present invention, within the Petunia hybrida EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEO ID 10 NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEO ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to 15 Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEO ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEO ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within 20 the contiguous sequence Ile-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

5.3 THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS

Any commonly known method can be used in the methods of the present invention to transform a plant cell with a recombinagenic oligonucleobases. Illustrative methods are listed below.

5.3.1 MICROCARRIERS AND MICROFIBERS

The use of metallic microcarriers (microspheres) for introducing large fragments of DNA into plant cells having cellulose cell walls by projectile penetration is well known to those skilled in the relevant art (henceforth biolistic delivery). United States

35 Patent Nos. 4,945,050; 5,100,792 and 5,204,253 describe general techniques for selecting microcarriers and devices for projecting them.

Specific conditions for using microcarriers in the methods of the present invention are described in International Publication WO 99/07865. In an illustrative technique, ice cold microcarriers (60 mg/ml), mixed duplex oligonucleotide (60 mg/ml) 2.5 M CaCl₂ and 0.1 M spermidine are added in that order; the mixture gently agitated, e.g., by 5 vortexing, for 10 minutes and let stand at room temperature for 10 minutes, whereupon the microcarriers are diluted in 5 volumes of ethanol, centrifuged and resuspended in 100% ethanol. Good results can be obtained with a concentration in the adhering solution of 8-10 μg/μl microcarriers, 14-17 μg/ml mixed duplex oligonucleotide, 1.1-1.4 M CaCl₂ and 18-22 mM spermidine. Optimal results were observed under the conditions of 8 μg/μl microcarriers, 16.5 μg/ml mixed duplex oligonucleotide, 1.3 M CaCl₂ and 21 mM spermidine.

Recombinagenic oligonucleobases can also be introduced into plant cells for the practice of the present invention using microfibers to penetrate the cell wall and cell membrane. U.S. Patent No. 5,302,523 to Coffee et al. describes the use of 30 x 0.5 µm and 15 10 x 0.3 µm silicon carbide fibers to facilitate transformation of suspension maize cultures of Black Mexican Sweet. Any mechanical technique that can be used to introduce DNA for transformation of a plant cell using microfibers can be used to deliver recombinagenic oligonucleobases for transmutation.

An illustrative technique for microfiber delivery of a recombinagenic oligonucleobase is as follows: Sterile microfibers (2 µg) are suspended in 150 µl of plant culture medium containing about 10 µg of a mixed duplex oligonucleotide. A suspension culture is allowed to settle and equal volumes of packed cells and the sterile fiber/nucleotide suspension are vortexed for 10 minutes and plated. Selective media are applied immediately or with a delay of up to about 120 hours as is appropriate for the particular trait.

5.3.2 PROTOPLAST ELECTROPORATION

In an alternative embodiment, the recombinagenic oligonucleobases can be delivered to the plant cell by electroporation of a protoplast derived from a plant part. The 30 protoplasts are formed by enzymatic treatment of a plant part, particularly a leaf, according to techniques well known to those skilled in the art. See, e.g., Gallois et al., 1996, in Methods in Molecular Biology 55:89-107, Humana Press, Totowa, NJ; Kipp et al., 1999, in Methods in Molecular Biology 133:213-221, Humana Press, Totowa, NJ. The protoplasts need not be cultured in growth media prior to electroporation. Illustrative conditions for electroporation are 3 x 10⁵ protoplasts in a total volume of 0.3 ml with a concentration of recombinagenic oligonucleobase of between 0.6 - 4 µg/mL.

5.3.3 WHISKERS AND MICROINJECTION

In yet another alternative embodiment, the recombinagenic oligonucleobase can be delivered to the plant cell by whiskers or microinjection of the plant cell. The so called whiskers technique is performed essentially as described in Frame et al., 1994, Plant 5 J. 6:941-948. The recombinagenic oligonucleobase is added to the whiskers and used to transform the plant cells. The recombinagenic oligonucleobase may be co-incubated with plasmids comprising sequences encoding proteins capable of forming recombinase complexes in plant cells such that recombination is catalyzed between the oligonucleotide and the target sequence in the EPSPS gene.

10

5.4 SELECTION OF GLYPHOSATE RESISTANT PLANTS

Plants or plant cells can be tested for resistance or tolerance to a herbicide using commonly known methods in the art, e.g., by growing the plant or plant cell in the presence of a herbicide and measuring the rate of growth as compared to the growth rate in 15 the absence of the herbicide.

6. EXAMPLE

The following experiments demonstrate the production of mutant

Arabidopsis thaliana EPSPS genes which are resistant to the herbicide glyphosate and
which allows the plant cells to maintain a growth rate

6.1 MATERIAL AND METHODS

6.1.1 ISOLATION OF ARABIDOPSIS THALIANA EPSPS cDNA

A 1.3 kb DNA fragment was amplified by PCR from an Arabidopsis cDNA

25 library using the primers AtEXPEXPM1 and AtEXPEXP2CM-2. The two primers were designed to amplify the cDNA from the mature peptide to the termination codon. The 5' primer AtEXPEXPM1 contains an XbaI site (underlined) and the 3' primer AtEXPEXP2CM-2 contains a BgIII site (underlined), sites which will be of use for cloning of the fragment into the expression vector.

30

AtEXPEXPM1

5'-GCTCTAGAGAAAGCGTCGGAGATTGTACTT-3' (SEQ ID NO:40)

AtEXPEXP2CM-2

35 5'-GCAGATCTGAGCTCTTAGTGCTTTGTGATTCTTTCAAGTAC-3' (SEQ ID NO:41)

The PCR band was excised from the agarose gel and purified (GeneClean, Biol). Its sequence was then confirmed as the mature peptide sequence of *Arabidopsis thaliana* EPSPS gene.

6.1.2 PREPARATION OF THE EXPRESSION VECTOR

The EPSPS coding region of the $AroE\ Bacillus\ subtilis$ gene was obtained by PCR using the following primers:

BsAroE5'Xba

5'-GCGTCTAGAAAAACGAGATAAGGTGCAG-3' (SEO ID NO:42) and

10

5

BsAroE3'BamHI

5'-GCGGATCCTCAGGATTTTTTCGAAAGCTTATTTAAATG-3' (SEQ ID NO:43).

The PCR fragment, lacking an initiation codon (ATG), was cloned in-frame to the pACLacIMH6RecA vector by replacing the ORF of *RecA* by digesting with XbaI and BamHI. PACLacIMH6RecA contained the LacI region of Pet21 at positions 1440 to 3176, the MH6 RecA at positions 3809 to 5188, chloramphenicol resistance gene at positions 5445-218 (5446 to 5885 and 1 to 218), and the p15A origin of replication at positions 581 to 1424. The coding region of *RecA* gene was cloned from *E.coli* in-frame with the start codon and 6 histidine linker (MH6) behind the LacZ promoter of pUC19.

6.1.3 CLONING OF THE ARABIDOPSIS EPSPS GENE INTO BACTERIAL EXPRESSION VECTOR

25 The Arabidopsis 1.3 kb PCR fragment was digested with XbaI and BamHI (compatible with BgIII) and cloned into the plasmid pACYCLacIMH6EPSPS, in place of the Bacillus gene.

The clones obtained (selected on chloramphenicol) were then sequenced and confirmed positive. One of the confirmed clones (pAtEPS-12) was selected and the ³⁰ junctions between the cDNA and the cloning plasmid were also confirmed to be identical to the expected sequences.

6.1.4 NOVEL POINT MUTATIONS IN THE EPSPS GENE

Ten different mutants of the *Arabidopsis thaliana* EPSPS gene were designed, (see Figure 2). For the mutagenesis experiments, PCR primers were designed with one, two or three mutations. The PCR reactions were performed using a regular

flanking primer (5'ATEPS-198: 5'- GAAAGCGTCGGAGATTGTAC-3' (SEQ ID NO:44)) and one of the mutation-carrying primers (see Figure 5).

The 353bp PCR fragments obtained were purified (Qiagen PCR Purification kit) and their sequence confirmed. The fragments were then digested with PstI (underlined in the primer sequences) and BamHI and ligated to the pAtEPS-12 vector, which had itself been previously digested with PstI and BamHI.JM109 (Promega) competent cells were used for the transformation and plated onto chloramphenicol-containing LB plates. Clones from each mutagenesis experiment were then isolated and their sequence confirmed.

6.1.5 GLYPHOSATE RESISTANCE ASSAYS

Electrocompetent cells of SA4247, a LacZ - Salmonella typhi strain, were prepared according to well known procedures (see Current Protocols in Molecular Biology, (Wiley and Sons, Inc.)). $30~\mu$ l of SA4247 competent cells were electroporated with 20 ng of each plasmid DNA encoding Arabidopsis wild-type and mutant EPSPS proteins, Bacillus 15 wild-type EPSPS, along with a mock transfection as a control. The settings for electroporation were $25~\mu$ F, 2.5KV and 200~ohms. After electroporation, the cells were transferred into 15~mls culture tube and supplemented with $970~\mu$ l of SOC medium. The cultures were incubated for 1~% hours at 37~C at 225~fpm. $50~\mu$ l of each culture were plated onto LB plates containing $17~\mu$ g/ml chloramphenicol (in duplicates) and incubated overnight at 37~C. On the following day, 5 colonies of each plate were picked and transferred onto M9 plates and incubated overnight at 37~C.

Colonies from the overnight incubation on solid M9 were inoculated into 4 ml of liquid M9 medium and grown overnight at 37°C. On the following day, 25 ml of liquid M9 medium containing chloramphenicol, IPTG and 17 mM or 0 mM Glyphosate 25 (Aldrich, 33775-7) were inoculated with 1-2 mls of each overnight culture (in duplicates), the starting OD (at 600 nm) was measured and all the cultures were normalized to start at the same OD. An OD measurement was taken every hour for seven hours. As a control of the bacterial growth, a culture of untransformed *Salmonella* was also inoculated into plain LB medium. In two independent experiments, the clones A₁₇₇I₁₇₈, A₁₇₇V₁₇₈, A₁₇₇L₁₇₈ and I₁₇₇ did not grow in M9 medium, therefore the glyphosate-resistance assays could not be performed on them.

6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES

35 One milliliter of overnight culture of each of the bacterial clones is inoculated into 100 ml of liquid LB medium containing chloramphenicol. The cells were

20

allowed to grow at 37° C until they reached an OD of 0.5-0.7 (approximately 3 ½ hours). IPTG was then added to the cultures to a concentration of 1.0 mM. The cells were grown five additional hours. They were then pelleted at 4000 rpm for 20 minutes at 4° C.

The isolation and the purification of the His-tagged proteins were performed following the Qiagen Ni-NTA Protein Purification System. Cell lysates and eluates were run in duplicates on 12.5% acrylamide gels. One of the gels was silver-stained for immediate visualization, the second gel was transferred onto Millipore Immobilon-P membrane, and blocked overnight in 5% milk in TBS-T. The membrane was then exposed to Anti-His primary antibody solution (Amersham Pharmacia biotech, cat# 37-4710), followed by exposure to Anti-Mouse-IgG secondary antibody solution. (NIF825, from Amersham Pharmacia biotech ECLWestern blotting anlysis system, cat# RPN2108). Washes and detection reactions were performed according to the manufacturer instructions. Autoradiograms were developed after 5 minutes exposure.

6.2 RESULTS

Cells containing a mutation in the EPSPS gene produced cells that were both resistant to the herbicide glyphosate and that had a substantially similar growth rate in the absence or presence of glyphosate, as compared to the wild-type cells, irrespective of the presence of glyphosate (see Figure 6).

It was also demonstrated that the *Arabidopsis* clones containing a mutant EPSPS gene expressed the mutant protein at substantially the same level as the wild-type protein (see Figure 7).

The invention claimed and described herein is not to be limited in scope by the specific embodiments, including but not limited to the deposited microorganism 25 embodiments, herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

30 A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference.

WE CLAIM:

10

- 1. A non-transgenic herbicide resistant plant, which plant expresses a mutant
 EPSPS gene product and which plant has substantially normal growth as compared to a
 plant expressing the wild-type EPSPS gene product.
 - A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product, which gene product has substantially the same level of catalytic activity as compared to the wild-type gene product.
 - 3. The plant according to claim 1 or 2 in which the herbicide is a member of the phosphonomethylglycine family.
- 4. The plant according to claim 3 in which the member of the 15 phosphonomethylglycine family is glyphosate.
- 5. The plant according to claim 1 or 2 in which the EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in Arabidopsis or 20 at an analogous amino acid residue in an EPSPS paralog.
 - The plant according to claim 5 in which the positions in the Zea mays paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.
 - 7. The plant according to claim 5 in which the positions in the *Brassica* napus paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
- 30 8. The plant according to claim 5 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
- 9. The plant according to claim 1 or 2 in which the plant is selected from the 35 group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape,

canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

- 10. The plant according to claim 5 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:
 - (i) Leu₁₇₃ Phe
 - (ii) Gly₁₇₇ Ala or Ile
 - (iii) Thr 178 Ile or Val or Leu
- 10 (iv) Ala₁₇₉ Gly
 - (v) Met₁₈₀ Cys
 - (vi) Arg₁₈₁ Leu or Ser
 - (vii) Pro182 Leu or Ser
 - (viii) Ser₉₈ -Asp
 - (ix) Ser₂₅₅ -Ala
 - (x) Leu₁₉₈ -Lys.
- 11. The plant according to claim 6 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with 20 the wild-type sequence:
 - (i) Leu₉₇ Phe
 - (ii) Gly₁₀₁ Ala or Ile
 - (iii) Thr₁₀₂ Ile or Val or Leu
 - (iv) Ala₁₀₃ Gly
- 25 (v)

30

- (v) Met₁₀₄ Cys
 (vi) Arg₁₀₅ Leu or Ser
- (vii) Pro₁₀₆ Leu or Ser
- (viii) Ser23 -Asp
- (ix) Ser₁₇₀ -Ala
- (x) Leu₁₂₂ -Lys.
- 12. The plant according to claim 7 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:
- 35 (i) Leu₁₆₉ Phe
 - (ii) Gly₁₇₃ Ala or Ile

- (iii) Thr₁₇₄ Ile or Val or Leu
- (iv) Ala₁₇₅ Gly
- (v) Met₁₇₆ Cys
- (vi) Arg₁₇₇ Leu or Ser
- 5 (vii) Pro₁₇₈ Leu or Ser
 - (viii) Ser₉₄ -Asp
 - (ix) Ser₂₅₁ -Ala
 - (x) Leu₁₉₄ -Lys.
- 10 13. The plant according to claim 8 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:
 - (i) Leu₁₆₉ Phe
 - (ii) Gly₁₇₃ Ala or Ile
 - (iii) Thr₁₇₄ Ile or Val or Leu
 - (iv) Ala₁₇₅ Gly
 - (v) Met₁₇₆ Cys
 - (vi) Arg₁₇₇ Leu or Ser
 - (vii) Pro178 Leu or Ser
- 20 (viii) Ser₉₄ -Asp
 - (ix) Ser251 -Ala
 - (x) Leu₁₉₄ -Lys.
- A method for producing a non-transgenic herbicide resistant or tolerant
 plant comprising
 - a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and
 - b. identifying a cell having a mutated EPSPS gene, which cell has substantially normal growth as compared to a corresponding wild-type plant cell.
 - 15. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising
 - a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and

35

b. identifying a cell having a mutated EPSPS gene, which encoded mutant EPSPS protein has substantially the same catalytic activity as compared to a corresponding wildtype EPSPS protein.

- 5 16. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is a mixed duplex nucleotide or a SSMOV.
- 17. The method according to claim 16 in which the mixed duplex nucleotide contains a first homologous region which has a sequence identical to the sequence of at least 6 base pairs of the first fragment of the target EPSPS gene and a second homologous region which has a sequence identical to the sequence of at least 6 based pairs of a second fragment of the target EPSPS gene, and an intervening region which contains at least one nucleobase heterologous to the target EPSPS gene, which intervening region connects the first and second homologous region.
 - 18. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is introduced by electroporation.
- 19. The method according to claim 14 or 15 which the mutant EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₅, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in Arabidopsis or at an analogous amino acid residue in an EPSPS paralog.
- 20. The plant according to claim 19 in which the positions in the Zea mays
 paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅,
 Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.
- 21. The plant according to claim 19 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, 30 Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
 - 22. The plant according to claim 19 in which the positions in the *Petunia* hybrida are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₅₁ and Leu₁₆₄.

23. The plant according to claim 14 or 15 in which the plant is selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape, turf grasses and *Brassica* sp.

24. An isolated mutant EPSPS protein comprising the amino acid sequence depicted in SEQ ID NO:2, in which amino acid position Leu₁₇₃ is replaced with Phe, Gly₁₇₇ is replaced with Ala or Ile, Thr₁₇₈ is replaced with Ile or Val or Leu, Ala₁₇₉ is replaced with Gly, Met₁₈₀ is replaced with Cys, Arg₁₈₁ is replaced with Leu or Ser, Pro₁₈₂ is replaced with 10 Leu or Ser, Ser₉₈ is replaced with Asp, Ser₂₅₅ is replaced with Ala or Leu₁₉₈ is replaced with Lys, which mutant EPSPS protein has increased resistance or tolerance to a herbicide, which herbicide is a member of the phosphonomethylglycine family.

15

5

20

25

30

ABSTRACT

The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

DNA sequence:

caaagccttgcacatgttgacgtgaacaccaaactaacacgtgtcatactgccagtggttatgataaatgctcataccat aacaaaatgtttatattagcaaagccgccaaagtgtaaacgaaagtttataaatttcatttctgtgatcttacgtaattg gaggaagatcaaaattttcaatccccattcttcgattgcttcaattgaagtttctccg

[transit peptide start]

ATGGCGCAAGTTAGCAGAATCTGCAATGGTGTGCAGAACCCATCTCTTATCTCCAATCTCTCGAAATCCAGTCAACGCAA ATCTCCCTTATCGGTTTCTCTGAAGACGCAGCAGCATCCACGAGCTTATCCGATTTCGTCGTCGTGGGGATTGAAGAAGA GTGGGATGACGTTAATTGGCTCTGAGCTTCGTCCTCTTAAGGTCATGTCTTCTGTTTCCACGGCGGAG

[mature peptide starts]

AAAGCGTCGGAGATTGTACTTCAACCCATTAGAGAAATCTCCGGTCTTATTAAGCTTCCTGGCTCCAAGTCTCTATCAAA TCGGATCCTGCTTCTCGCTGCTCTGTCTGAGGTATATATCACTTCGTTTCGTCCTTCTCTGTAATCTGAACTTAGATTAT AAAGATTGATACTTTACCATTTTGCTGTGGTTTTATAGGGAACAACTGTAGTGGACAACTTGTTGAATAGCGATGACATC AATTACATGCTTGATGCGTTGAAGAGATTGGGACTTAATGTGGAAACTGACAGTGAAAATAATCGTGCTGTAGTTGAAGG ATGTGGCGGGATATTCCCAGCTTCCATAGATTCAAAGAGTGATATCGAACTTTACCTCGGTAATGCA<u>GGAACA</u>GCAATGC GTCCACTTACCGCTGCGGTCACTGCTGCAGGTGGAAACGCAAGGTAGATTGAAGGAGTTGATGCTTCTTGGTATTTGATG TTTAAGGAATGGAGCTTTTGTTGATGCTTTATGATCCATTTATTCCAGTTATGTGCTTGATGGGGTGCCTCGTATGAGAG CCTGTTCGTGTCAACGCTAATGGTGGCCTTCCCGGTGGAAAGGTTAGATCTTGCAAATGGCATGTGAATATGTAATCTCG TTCCTTACTCTATGAACACTTGCAGAAATGTGTGTTCATCATAGCCTTAGCTTGACAAGATTTCAGTTTTTAATCTACTC TCAACGGATGGATCCTAAAATAGAATCGGATTTGGTGATTGGTTTTCGTTCTCGATTACCGTTTTCGTTGTATGATTTCT TGATTAACAATTAGGAGACATGTTATGCATTTGCAGGTGAAGCTTTCTGGATCAATTAGTAGTCAGTACTTGACTGCTCT TGACATTGAAGTTGATGGAACGTTTCGGGGTTAGTGTCGAGCATAGTGATAGCTGGGATCGTTTCTTTGTCAAGGGCGGG CAAAAATACAAGTAGGAGTTATTCTTTCTTCCTTTTCTGAAATCACATCCCTTAGCTTGACAATATAATGACTAAAAGG TGAATGATTCAGGTCTCCGGGTAATGCGTATGTAGAAGGTGATGCTTCTAGTGCATGTTATTTCTTGGCTGGTGCTGCCA TTACCGGTGAAACTGTCACAGTCGAAGGTTGTGGAACTACCAGCTTGCAGGTAATATTTGTACACTGAATCATCGACGAG $\tt GCTGTTAAGTTATAGTGAAATTCGTCTAGGTCAAAGTTTCATCTTTTGACAAGTTGTATATAACATATTCGCAAGATTC$ TAAGCTCAATTTTTGTGATGAATCTCTAGGGAGATGTAAAATTCGCCGAGGTCCTTGAGAAAATGGGATGTAAAGTGTCC TGGACAGAGAACAGTGTGACTGTGACAGGACCACCTAGAGATGCTTTTGGAATGAGACACTTGCGGGCTATTGATGTCAA CATGAACAAAATGCCTGATGTAGCCATGACCCTTGCCGTCGTTGCTCTTTTGCTGACGGTCCAACCACCATTAGAGATG $\tt GTAAGTAAAAAGCTCTCTTTATAATTAAGGTTTCTCAATATTCATGATCACTTAATTCTGTTTGGTTAATATAGTGGCT$ TTCTGTCTCTTGACAGTGCTCATTCTAAGTAATTAGCTCATAAATTTGTGTGTTTGTGTTCAGCTGGGAGCTACAGTGGA AGAAGGTTCAGATTATTGTGTGATAACTCCGCCCAAAAAGGTGAAAACGGCAGAGATTGATACATATGATGATCATAGAA TGGCAATGGCATTCTCTTGCAGCTTGTGCTGATGTTCCAATCACCATCAACGACTCTGGTTGCACCAGGAAAACCTTC CCCGACTACTTCCAAGTACTTGAAAGAATCACAAAGCACTAAacaataaactctgttttttcttctgatccaagctt

FIG. 1A

Protein sequence:

MAQVSRICNGVQNPSLISNLSKSSQNKSPLSVSLKTQQHPRAYDISSNGLKKSGNTLIGSELPELKVMSSVSTAE
KASETUV,DEIRIGGLIKLDGSKSISSNILLIALALSEGTTVVMLLINSDINTMULDALKRLGLIVNTGSENNRAVV
EGCGIFPASIDEKSDIELYLGNAGTANDLTAAVTAAGGNASYVLDGVPRMERPIGDLVVGLKQLGADVECTLG
TRCPPVRVMANGGLPGKVKLSGGISSQUTTALLASSPLALAGDVEIEIVDKLISVPYVEMTLKLMERFGVSVEHSD
SWDRFFVKGGKYKSFGNATVEGDASSACYFLAGAAITGSTVTVEGGTTSLGGUVKFAEVLEEWGCKVSWTENSV
TVTGPPRDAFGMRHLKAIDVNNKMPDVAMTLAVVALFAADFTTIRDNSARVKETERMIAICTELRKLGATVEEG
SDYCVITPFKKVKYTAEIDTYDDHRMAMAFSLAACADVPITINDSGCTRKFTPDYFGVUERITKH

FIG. 1B

_													
Arabidopsis thaliana wild type sequence:													
	Position	$_{L}$	G		Α	G	T	Α	M	R	182 P CCA	L	
		Arab	idops	is tha	liana	mutai	ıt seq	uence:	<u>s:</u>				
	Name A ₁₇₇	CTC L	GGT G	AAT N	GCA A	GCA A	ACA T	GCA A	ATG M	CGT R	CCA P	CTT L	
	I ₁₇₈	CTC L	GGT G	AAT N	GCA A	GGA G	ATA I	GCA A	ATG M	CGT R	CCA P	$_{L}^{\mathrm{CTT}}$	
	A ₁₇₇ I ₁₇₈	CTC L	GGT G	AAT N	GCA A	GCA A	ATA I	GCA A	ATG M		CCA P	CTT L	
	I ₁₇₈ S ₁₈₂	$_{L}^{\mathrm{CTC}}$	GGT <i>G</i>	TAA N	GCA A	GGA G	ATA I	GCA A	ATG M	CGT R	TCA S	CTT L	
	A ₁₇₇ S ₁₈₂	CTC L	GGT G	AAT N	GCA A	GCA A	ACA T	GCA A	ATG M	CGT R	TCA S	CTT L	
	A ₁₇₇ I ₁₇₈ S ₁₈₂	CTC L	GGT G	AAT N	GCA A	GCA A	ATA I	GCA A	ATG M	CGT R	TCA S	CTT L	
	V ₁₇₈ S ₁₈₂	CTC L	GGT G	AAT N	GCA A	GGA G	GTA V	GCA A	ATG M	CGT R	TCA S	CTT L	
	L ₁₇₈ S ₁₈₂	CTC L	GGT G		GCA A	GGA G		GCA A	ATG M	CGT R	TCA S	$_{L}^{\mathrm{CTT}}$	
	$A_{177}V_{178}$	CTC L	GGT G		GCA A	GCA A	GTA V	GCA A	ATG M	CGT R	CCA P	CTT L	
	$A_{177}L_{178}$	CTC	GGT	AAT	GCA	GCA	TTA	GCA	ATG	CGT	CCA	CTT	

FIG. 2

10 20 30 40 50 60 70 80 90 20 ARGGGGGAAGTGGGGAAATCTGGCAAATCTGGAAATCTGGCAAATCTGGCAAATCTGGGGGAAATCTGGGGGGAAATCTGGGGGGAAATCTGGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCTGGGAAATCAAATCAAATCAAATCTGGAAAATCAAATCAAAAATCAAAAAA	10 110 120 130 140 150 150 150 150 150 150 150 150 150 15	200 210 220 230 240 250 250 260 270 280 280 280 280 280 280 280 280 280 28
10 ATGGCGCAAG ATGGCGCAATG ATGGCACAAAGGGGGGGGGG	TTTCT	201 201 192 addarcjupali 180 addarcjupali 180 articartifali
	2 9 9 10	

rcchanterantelalifecajtecijecijerecencencencencencencencencencencentencentencentencentencentencentencentencente petaroacDNN.SEQ riconaricing respanted in contranspace de contranspante de mensante de contranspante de manda de contranspante znepsps.SEQ 360 350

περέλοποειππεςελλετεστερέληςπαρετορετέρουστά κουρολόλου λολολού το ληλοκοποτή ολολοκό το τρομοτή επρολόγου τη 490 480 470 460 450 440

petaroacDNA.SEQ zmcpsps.SEQ ӈҧӿӄ҇ӗӧӡ҈тӧѧѧӧѧѧҁҁҭѵҁӡҁҫӷӷҧѧӆҁҭӧѧѧ҅ҁҁҭӧӒӒѧҁҭӯҁҭѧ҄ѧ҆ѧ҆ҁѹҁҁҭӡҭҧ҅ӓѧӓҕӿҭҁ҅ҫӧӯӷ҅Ҟӄѧӿӷӄ҅ӷҭӷҫҼҭӳҪҼҭҋҪҭ ingasaáct makakatot tástatatrataraangasakanakátra anakanagatáh armán tagatasatatah natracakatra---kadh

> 380 380 167

392

280

292

280

atepspscDNA.SEQ bnepscDNA.SEQ ңесталаны она отастстства вана тастана старан серене старан от старан от старан от старан от старан от старан о THE DANGERGE THAT THE GRANCE THAT A COTOGO THAT IS CAN A COTOGO C myčojáladien namahattion actitassáki tágaládak jaka acataga actica activa activa activa activa activa activa a 580 570 260 550

atepspecdnn.seQ briepsecdnn.seQ petazoacdnn.seQ zmepsps.seQ	arepspscDNA.SEQ bnepscDNA.SEQ petaroacDNA.SEQ zmepsps.SEQ	atepspscDNA.SEQ bnepscDNA.SEQ petaroaCDNA.SEQ zmepsps.SEQ	atepspucDNA.SEQ bnepccDNA.SEQ , petaroacDNA.SEQ , zmepsps.SEQ	snewangondagachitetsanissee 1000 1010 1020 1040 1050 1060 1070 1080 1090 1090 1090 1090 1090 1090 109	1130 GGCT atepspacdNA.SEQ GGCC zmepspa.SEQ GGCC zmepspa.SEQ
680 690 retriggachact a retriggedentstr cerreggachant	780 reconstrantan reconstrated reconstrated reconstrated	880 890 arregaacetryrcese arregaacetryrcer arregaecetryrcer arregaecetryrcer	980 980 GAAGGIGATGCTTCTA GAAGGTGATGCTTCTA GAAGGTGATGCTTCA GAAGGTGATGCTCA	1080 109 3ATGTAAAARTCGCCG GATGTGAAATTRGGTG GATGTGAAGTTTGCTG	1180 11 Vroanch chrifteerens krichegelderringerense krichegelderrense krichense krichense
570 570 TIGATOTTGAATGTPAC STGATGTTGATTGTTT CAGATGTTGATTGTTT	770 TPGTCNGTACTTGAC SCAGTCATTGAC SCAGTCAGTACTTGAC SCAGTCAGTACTTGAC	1 AATGACATTGAAGTTG AATGACATTGAAGTTG GATGACATTGAAGTTG	910 CCGCCTAATCCGTATCTA CCTGCTAATCCTTATCTA CCTGGANAACCTTTTCCC CCTGAAAATCCCTATCTT	1060 1070 Crhccacctrachagash Chactractrcaedsan Cananartrancaedsa Caccactrracaedsa	1160 1170 nagaangetifiyasa paeagangetifiyasa paeagaangetigasa paeagaangetigasa paeagaangetigasa
60 60 STANGCAGCTTGGTG STANACAGCTTGGTG CTTANACAGCTTGGTG	750 760 rrrcredantcaatrae rrrcredantcaatrae rrrcredantcaatrae rrrcredantcaatrae	850 CTCTTCCATATGTTGAAA CTCTTCCATATGTTGAAA GTGTACCTTATGTCGAGA	950 950 AGNANTACNAGTUTCC AGNANTACNAGTUCCC AGNANTACNAGTUCCCC	1050 1050 CCAAGGTTGTCGAAC FCAAGGTTGTCGAAC FTGAAGGTTGTGGAAC	1150 1250 rigitahanasakaran parichanasakaran parikanasakaran rigitahanasakana
640 GATTROGITGETT GATTROGITGETT GATTROGITGENGGTT CACTROGITGETTGETT	30 740 agreemagreame agreemagreame ganggamegreame gereecanggreame	840 330 840 ATCGATANACTGATAT ATCGATANACTGATATA	930 940 TTGTCAAGGGCGGC TTGTCAAGGGCGGTC TTGTCGAAGGGCGTC TTGTCGAAGGGCAGGTC	1030 1040 Grannforrercher Grannforrercher Greenherercher Greenherercherer	1130 1140 TAGAGAACAGTGTGAC GAGAGAACAGTGTCAC CAGAGACTAGCCTAAC
620 63 GRANGACCTRATAGGG SCRANGACCTRATAGGG SCRANGACCTRATAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	720 7. AAATGGTGGCCTTCCC PAATGGTGGCCTTCCC PAAGGGGGGGGGGTCTCCT	820 BYOGAGATTCACATTC GTCGAGATTGAGATC GTCGAGATTGAAATC	POTEGRACATI COMPANY OF THE STATE OF THE STAT	1020 1020 igracingcehinacië sënocijechinacië	1120 GRANGETOTICEGA GRANGETOTICEGA GRANGETOTICEGA SCGARGETACHTGGA
610 610 620 630 630 640 650 650 660 670 680 690 690 690 CETATAGENERAL CHARACTAGENERAL CHARACTA	CETGATICASIAN CONTROLL TO	coccaccatatostratostratos como se	recreative decreative designations are some some some some some some some som	этосимосидающий тисков по том по то	EGROPAGE CHARTER CTTGGCTGGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
	(92 GCCTC (92 GCCTCC (80 GTCCTCC	164 GCDCACK 192 INSCINCT 790 AĞCMCC		664 GTGGA 992 GTGG 980 GTGGG	2007

		Jas.	SEO
The second secon		atepspscDN	A THE TARGET SALE IN THE TARGET SALE OF THE TARGET
1	1290	CGCTAGCT	The Contraction of
-	1280	TOTA OXOXUM	TO THE PURPLE OF THE
-	1270	a TOS CONTRACTOR DE LA	CCAACCACCA
	1270 1270 1		Tecteaceer
The state of the s		757	PYGCTCTCT
1		1240	CTYNGCCGTCC
1		1230	AGCCATGACC
		1220	VIOLENT CATIGOTA
	-	1210.	A PACTOR DE DE
	-	1200	0.0000
	-		1

g

arteangreaacareáadhaanteccreanstroccareacacatecreatrordecactronecactrantangreccacacacacacacacacacacacacacacaca APPRATERIORACATGAMCAAGAAGCCCCGAAGGCCAACGACGACTGCCGTGCCCCCTTTGCCGAACGCCGACAGCCAACAGAGACGTGGCTCCCT 2MBPSPB.5B0 2.80

1280 (GRIGNOTTANGORGKORGKORGKORTTOCCHNITGCACACACGCTTAGAAACCTTGGAACCTTACAGGTTGAAGATTATTATTATTATTATTATTATTACCC DREPSODNA.SBQ 1064

<u> боссывываетвына вертительный правтерительный в праводителестителестивноставителести</u> а серевосим. SBQ 1490 1480 1470 1460 1450 1440 1430 1420 1410

1164 eteedájádásásetjánasetlansssonarssánasásátasásatajánasssottatásásetteresteresteresterásásásásásásásata zmepsps. SBQ 1380 ACCAGCHARGOTISARACCGGCGGAGAURTARACCTRACARTACARTACARTACACGARGGCGARGGCGTTCTFGCAGCTTTCGAGCTTCTACTACTACCAATC

1180 AATGANGCANGCACGCGGAAAACCPINCCTINACTINGTINGTINGTINGTINGTICACCAGAACCAAAGCAATTSA

atepspscDNA.SEQ bnepscDNA.SEQ petaroacDNA.SEQ zmepsps.SEQ

					And the last of the last	-	DESCRIPTION OF THE PERSON NAMED IN	THE RESIDENCE AND ADDRESS OF THE PARTY AND ADD				
1		-			-	-		- 6	. 6	60	100	
	C	20	30	40	20	99		₹.	0.0	ζ-		
	PRO TENSION OF PETITION OF PET		-	-	1			The same	TO TOTAL OF	TYPETECT TYPE	NS ISASSO	atensps, PRO
		CONTRACTOR AND THE	DECENT OTICY VO	TOVEGOUDO	TO COMPLY KES	CHILIGSELR	377	VINSSVSTAL	SINDER VICE	THE PROPERTY OF		
	MAQUSRICNGVQNP-SLISNLSASSAGNASTAS CHALCE HIS TOTAL CONTROLL OF THE STANDARD SKILL STANDARD SKELS AND DREPSED FROM	SETSNESVES	MASTERS COLUMN	TANK TONE		Carried tree of the Country In	שנות	TOWN CETTOR CT	PKASRITUTOR	TREESGLING	PCSKSLSN	onepsps.PRO
	PORCEDITION	WITCH SKSNO	NKSPFSVSLKT	HOPK	SASSINGLIKKSO	GIMENGOVIR	VALUE OF THE PARTY				This property of	Odd roardog
	THE SOUTH THE STATE OF THE STAT		0000000000	4.5	M. T. M.	CHARRIST	PMOKECSER	ISASVATAC	OKPSEIVLOR	TKATSGIVE	PGSGSDSN	herar og 'Evo
	MAQINIMAAQGIQTL-MPNSNFHXPQVFKSSSFLVFGSAKALKASAKLKASAKLKASAKALPGSBS-PRO	MENSNEHKPOV	PKSSSFLVFG	SAKATATA	or.	-			DEPT VIOL	TKELSGTVKL	PGSKSLSN	PRO CHARLES CHARLES CONTROL SCHOOL SHOP SHOP SHOP SHOP SHOP SHOP SHOP SHOP

AG-

100 riiliaaseotuvudailasdoinvaloalakelsinnerdsnankavvesoogolepasidsksdielaisaasaarpaarpaataasavidsovermerdioduv diepopo. Pro 100 ritajaalskotinydnilssddihencalkilgihueedsangrypeocoglepygreskeeigifilgarcharpleaanturgonsrytloyperbereeisdly pelakoa. Pro КІТДЬРАКБЕЎТУЎОКІТЯКЕОЧНУКІСЯЛАГІСБУРВАЦКАКПАУУУССССКЕРУ-БРАКЕБУОЛЕГСКАКТУЛАКТАЛАСКАТУЎЛЬСЎГККЕЙГІСТУ 2мерзря. РВО VIIIIAMESSOTIVVDNILASDDINVALDALKRAGIAVETDSENNRAVVEGOGGIPPASIDSKSDIEJTIGANGTANREPLIRAGVINAGGANS VYLIGYPRINRRPLODLY 180 170 140 2.1.0

petaroa. PRO 138 VOLKOLÓGÍDVÍCELGTÍDCEPVRVNGLGGLÞQGKVKLSGSTSSQYLSKALMAÐELNLGÖVRLÖKTÍKKLÍSIÞÝVENTÍALÁBRÆGKRÁBÍSDSÚÐRFÝTKGGÓKYKSPKNA ZMEPSPS.PRO IGIKŌRGADVECTILGTNOPPVRVRANGGLPGGRVYKLSGSISSQVITRALIMSAPLĀLGDVIZIELVDĪĢLISVPLVRATKLĀRIRĒGVSVERSISNARĀRĀVRĀGOQRYKSPGRA võlkolohivas tilotnup puhvinnangilegekulalsest Sõõttitalinaataaledatelet toka isvervähtilaarregismitetentestaka DGIKQIGABUDG PLGIKOP PUTUSKGGL ROGKVILISGSI SSQYLITABIDA PLALIBIKA LISTOVI KATILILIGAK POLISGWA KATIKA BOGKYKSPGKA 210

	0	0
	3. PR(9. PR(
	epspe	epsp
	v ate	V ba
20-	SWR	SWR
•	TROV	TRDV
_	DTI	DIL
75	TAN	EX.
	NYAZZ	AVVA
010	Man .	T. L.
•	1	
_	T. C. L.	THE PERSON NAMED IN
400		
-) in
90	-	FGMK
~		PRDA
	-	VICE
380	+	LASM
	-	SWIE
. 0	.]	SCKV
ř	,	EKN
		NEW.
- 95	3-	SDVR
		CSEC
	2	CCL
- 0	2	TVEC
		GET
- :	٥٠- ١٠-	PALT
		FLAG
	0	SACY
1	33	SPOS
		S
	350 350 400 410 420 430	330 340 350 360 370 380 390 400 410 420 434 434 340 350 360 370 370 380 390 400 400 400 400 400 400 400 400 400 4

petaroa.PRO 218 YVEGBÄĞGSÖYTLAGAATIGGIYYYVEGCETYSLGGBYXFABYLIBMGAXKYTWIEFFSYTVÄYĞPFREFGRIXHLIKALIĞTARKYEDİAMTLAYTALADGETALADVASMRY ZMƏDEDS.PRO 200 құйдық құқтылы түреттір құрық қарық қарық қарық қарық құрық құрық құрық құрық құрық құрық құрық құрық құры 330 құйдық құрыды құрық құр

						1			
	440	450	460	470	480	490	200	510	520
		-		The same of the same of	"ENENIUS CHAIN	CT A LOZDAD	THYNDSCCTRE	TPPDYFOUL	BRITKH
34	XETERMIAICTE	TRKLÇATVE	SCSDYCVITTE	KKYKIMETER	TOTAL MENTAL		Mamoodia	TYPOTY TOTAL	RST TIKH
30	KETERMIAICHE	TRKLGATVE	SCSDYCVITPP.	AKVKPAEIDI	YDDHREANA	STRACADVE	WITNE GOTTON	TUTTAL	OOVSKH

ХЕРВКИТАТСТВЕЛЯКІ САТИВБЕРВУСТІТРРЕККІМУТІЛІРУВІБНИМАМАРБІЛАСАБУРУТІМІРОСТЯКТЕРМУТВУКІМ KETERNVAJRTELIKOGASVEBGEDYCIITP PERKLNVTAIDTYDDHRAMAR SGARGAEVPYTR BPRGCTRKTFPDY FDVLSTFYRN

430 430

atepsps. PRO bnepsps. PRO petaroa.PRO zmepsps.PRO

Oligo Name Oligo Sequence (5'→3')

ATEPS-A177

OGITICOAOCTGCAGCAGTGACOGCAGOGGTAAGTGGAOGCATTGCTGTTGCTGCATTACOGAG

ATEPS-AI

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG

ATEPS-IS

OGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTATTCCTGCATTACCGAG

ATEPS-AS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTGTTGCTGCATTACCGAG

ATEPS-ATS

OGITTICCACCIGCAGCAGIGACCGCAGCGGTAAGIGAACGCATIGCTATTGCTGCATTACCGAG

ATEPS-I177

OGTITICCACCIGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTATTGCATTACCGAG

ATEPS-VS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTACTCCTGCATTACCGAG

ATEPS-LS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTAATCCTGCATTACCGAG

ATEPS-AV

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTACTGCTGCATTACCGAG

ATEPS-AL

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTAATGCTGCATTACCGAG

FIG. 5




FIG. 6




FIG. 7

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et sec, underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et sea, below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

and for which a patent application:

is attached hereto and includes amendment(s) filed on (d applicable)

□ was filed in the United States on as Application No. (for declaration not accompa

with amendment(s) filed on (if applicable)

was filed as PCT international Application No. on and was amended under PCT Article 19 on (gapphenble)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

-	EARLIEST FOREIGN APPLICAT	ION(S), IF ANY, FILED PRIOR	TO THE FILING DAT	E OF THE APPLICATION
20 10 (040)	APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
				YES □ NO □
0 = 0				YES □ NO □

	YES D NO D
I hereby claim the benefit under Title 35, United States	s Code, §119(e) of any United States provisional application(s) listed be
APPLICATION NUMBER	FILING DATE
60/158,027	October 7, 1999
60/173,564	December 30, 1999

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

			STATUS	
APPLICATION SERIAL NO.	FILING DATE	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY. As a named inventor, I hereby appoint S. Leshe Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshali (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Charles E McKenney (Reg. No. 22795), Philip T Shannon (Reg. No. 24278), Francis E Morris (Reg. No. 24615), Charles E Miller (Reg. No. 24576), Gidon D Sterm (Reg. No. 24746), Joint Ja. Lautz- Jr. (Reg. No. 27814), Brian M Possant (Reg. No. 28462), Brian D Coggio (Reg. No. 2624), Roy J. Radding (Reg. No. 28749), Stephen J Harbulak (Reg. No. 29166), Donald J Goodell (Reg. No. 19766), James N. Palis (Reg. No. 25510), Thomas E Frebel (Reg. No. 29258), Laura A Coruzzi (Reg. No. 30742), Jeninfer Gordori (Reg. No. 30753), Alland A Fanucci (Reg. No. 30256), Geraldine F: Baldwin (Ban. 2123), Victor N. Balancia (Reg. No. 3123), Samuel B Abrams (Reg. No. 3005), Stevent I Wallach (Reg. No. 35402), Marcia H Sundeen (Reg. No. 3093), Paul J. Zegger (Reg. No. 3826), Laura (Reg. No. 31010), Bruze J Barter (Reg. No. 3297), Adrane M Anter (Reg. No. 32063), Thomas G 2005), Thomas G 2005), Thomas G 2005, Marcia H Sundeen (Reg. No. 31063), Marcia H Sundeen (Reg. No. 31064), Marcia H Sundeen (Reg. No. 31064), Marcia H Sundeen (Reg. No. 310 20006 and 3300 Hillyiew Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith

THE RESIDENCE OF THE PARTY OF T

SEND CORRESPONDENCE TO: PENNIE & EDMONDS LIP DIRECT TELEPHONE CALLS TO.

1155 Avenue of the Americas PENNIE & EDMONDS LIP
New York, N Y 1003-62711 (212) 790-2803

2	FULL NAME OF INVENTOR	BEETHAM	PETER	R.	
0	RESIDENCE & CITIZENSHIP	CARLSBARD	STATE OR FOREIGN COUNTRY CALIFORNIA	AUSTRALIA	
	POST OFFICE ADDRESS	STREET 7128 TANAGER DRIVE	CARLSBAD	STATEOR COUNTRY CALIFORNIA	ziр сооь 92009
	FULL NAME OF INVENTOR	LAST NAME AVISSAR	PATRICIA	L.	
2 0 2	RESIDENCE & CITIZENSHIP	EAST BRUNSWICK	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 32 REVOCK ROAD	EAST BRUNSWICK	STATE OR COUNTRY NEW JERSEY	2IP CODE 08816
	FULL NAME OF INVENTOR	LAST NAME WALKER	FIRST NAME KEITH	MIDDLE NAME A	
2 0 3	RESIDENCE & CITIZENSHIP	SAN DIEGO	STATE OF FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CHIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 13315 ROXTON CIRCLE	SAN DIEGO	STATE OR COUNTRY CALIFORNIA	2IP CODE 92130
	FULL NAME OF INVENTOR	LAST NAME METZ	FIRST NAME RICHARD	A.	
2 0 4	RESIDENCE & CITIZENSHIP	LAWRENCEVILLE	STAIL OR POREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	37 WINTHROP ROAD	LAWRENCEVILLE	NEW JERSEY	2EP CODE 08648

HEREBY DECLARE THAT ALL STATEMENTS MADE HEREIN OF MY OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILEFUL FLASE STATEMENTS AND FURTHER SECTION 1001.

OF TITLE 18 OF THE UNITED STATES CODE AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION OR ANY PATENT ISSUING THEREON.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 205
PETER R BEETHAM	PATRICIA L AVISSAR	KEITH A. WALKER
DATE	DATE	DATE
SIGNATURE OF INVENTOR 203		
RICHARD A METZ		

(2) NY2 - 1128607.1

EXPRESS MAIL NO.: EL 501 634 414 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Beetham et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For:

NON-TRANSGENIC HERBICIDE

Attorney Docket No.: 7991-086

RESISTANT PLANTS

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: October 10, 2000

(Reg.No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090

Enclosures

SEQUENCE LISTING

<110> Beetham, P.

```
Avissar, P.
             Walker, K.
             Metz, R.
       <120> NON-TRANSGENIC HERBICIDE RESISTANT PLANTS
       <130> 7991-086
       <150> 60/158.027
       <151> 1999-10-07
       <150> 60/173.564
       <151> 1999-12-30
       <1.60> 44
       <170> FastSEO for Windows Version 3.0
       <210> 1
       <211> 2763
       <212> DNA
       <213> Arabidopsis thaliana
       <400> 1
 cccttcatgt cttttgtaga aaccccatta tctttcttag ggcccaattg aaaacccaca
ttttctttca cctaacccac caaaqccttq cacatqttqa cqtqaacacc aaactaacac
gtgtcatact gccagtggtt atgataaatg ctcataccat accagagtca tagagttttt
ggttggtgaa agatttgaeg gatgeettet teteatttet caccaactee etecaaacee
aacaaaatgt ttatattagc aaagccgcca aagtgtaaac gaaagtttat aaatttcatt
totgtgatot taogtaattg gaggaagato aaaattttoa atooccatto ttogattgot
tcaattqaaq tttctccqat qqcqcaaqtt agcagaatct qcaatggtgt gcagaaccca
totottatot coaatototo gaaatooagt caacgcaaat otocottato ggtttototg
aagacgcagc agcatccacg agcttatccg atttcgtcgt cgtggggatt gaagaagagt
 gggatgacgt taattggctc tgagcttcqt cctcttaaqq tcatgtcttc tgtttccacg
 qcqqaqaaaq cqtcqqagat tqtacttcaa cccattagag aaatctccqq tcttattaaq
 cttoctgget ccaagtetet atcaaategg atcetgette tegetgetet gtetgaggta
 tatateactt cotttectec ttetetotaa tetoaactta gattataaag attgataett
 taccattttq ctqtqqtttt ataqqqaaca actqtaqtqq acaacttqtt qaataqcqat
 qacatcaatt acatqcttqa tqcqttqaaq aqattgggac ttaatgtgga aactgacagt
```

120

180

360 420

480

540

600

660

720

780

840

960

1020

1080

1140

1200

1260

1320 1380

1440

1500

1560

1620

1680

1740

1800

acaagattto agttittaat otactotoaa oggatogato otaaaataga atoggattitg gtgatlggtt thogttotog attacogtit togttgatag attotigat tacacattag gagacatgtt atgoattige aggigaaget tictiggatoa attagtagto agtactigac tgototigoto atgictigoto cottagetot tggagacogto gagatigaga titgicgataa attaaattic gitocatatig tigaaatgac attigaagitg atggaacgit tigicggataa tgicgagcat aggatagot gggatogtit cittigicaag ggoggogaaa aatacaagia qaaqttatto titticticot tittotigaaat cacatocott agottigacaa tataatgaci

qaaaataatc qtqctqtagt tgaaggatgt ggcgggatat tcccagcttc catagattca

aagagtgata togaacttta cotoggtaat goaggaacag caatgogtoo acttacogot

geggteactg etgeaggtgg aaaegeaagg tagattgaag gagttgatge ttettggtat

ttgatgttta aggaatggag cttttgttga tgctttatga tccatttatt ccaqttatqt

gettgatggg gtgeetegta tgagagaaag acctataggg gatttggttg ttggtettaa

geagettggt getgatgttg aatgtactet tggaactaac tgeceteetg ttegtgteaa

eqetaatqqt qqccttcccq qtqqaaaqqt tagatcttgc aaatqqcatg tgaatatgta

atotoqtico ttactotatg aacactigca gaaatgtgtg ttcatcatag cottagottg

aaaaggtgaa tgattcaggt ctccgggtaa tgcgtatgta gaaggtgatg cttctagtgc atgttatttc ttggctggtg ctgccattac cggtgaaact gtcacagtcg aaggttgtgg aactaccago ttgcaggtaa tatttgtaca ctgaatcatc gacgaggctg ttaagtttat agtgaaattc gtctaggtca aagtttcatc ttttgacaag ttgtatataa catattcgca agattctaaq ctcaattttt qtqatqaatc tctaqqqaqa tqtaaaattc gccgaggtcc ttgaqaaaat qqqatqtaaa gtgtcctgga cagagaacag tgtgactgtg acaggaccac ctagagatgc ttttggaatg agacacttgc gggctattga tgtcaacatg aacaaaatgc ctgatgtagc catgaccett gccqtcqttq ctctctttqc tgacqqtcca accaccatta qaqatqqtaa qtaaaaaqct ctctcttata attaaqqttt ctcaatattc atqatcactt aattotqttt qqttaatata qtqqctagot qqaqaqtaaa qqaqacagaa aggatgattg ccatttgcac agagettaga aaagtaagag attettatet etetettet gtetettgac agtgctcatt ctaagtaatt agctcataaa tttgtgtgtt tgtgttcagc tgggagctac agtggaagaa ggttcagatt attgtgtgat aactccgccc aaaaaggtga aaacggcaga gattqataca tatqatqatc ataqaatqqc aatqqcattc tctcttqcaq cttqtgctga tgttccaatc accatcaacg actotggttg caccaggaaa accttccccg actacttcca aqtacttqaa aqaatcacaa aqcactaaac aataaactct gttttttctt ctgatccaag ctt

1860

<210> 2 <211> 520

<212> PRT

<213> Arabidopsis thaliana

<400> 2

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu 10 Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val 20 25 30 Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser 40 45 Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg 55 Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Glu Lys Ala Ser Glu 70 75 Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro 85 90 Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser 100 105 Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser Asp Asp Ile Asn 120 125 Tyr Met Leu Asp Ala Leu Lys Arg Leu Gly Leu Asn Val Glu Thr Asp 135 140 Ser Glu Asn Asn Arg Ala Val Val Glu Gly Cys Gly Gly Ile Phe Pro 160 145 Ala Ser Ile Asp Ser Lys Ser Asp Ile Glu Leu Tyr Leu Gly Asn Ala 165 Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr Ala Ala Gly Gly 180 185 Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro 195 200 Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly Ala Asp Val Glu 215 220 Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val Asn Ala Asn Gly 225 230 235 Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln 245 250 255 Tyr Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala Leu Gly Asp Val 265 260

```
Glu Ile Glu Ile Val Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met
       275
                         280
Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Val Glu His Ser Asp
   290
                      295
                                        300
Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro
                 310
                                    315
Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Cys Tyr Phe Leu
             325
                               330
Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly
          340
                            345
Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys
      355 360
                                           365
Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly
                    375
                                       380
Pro Pro Arg Asp Ala Phe Gly Met Arg His Leu Arg Ala Ile Asp Val
                 390
                                   395
Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala
             405
                                410
Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg
                            425
                                               430
          420
Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys
      435
                      440
                                           445
Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro
              455
Pro Lys Lys Val Lys Thr Ala Glu Ile Asp Thr Tyr Asp Asp His Arg
                                475
               470
Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Ile Thr
             485 490
Ile Asn Asp Ser Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln
       500
                            505
Val Leu Glu Arg Ile Thr Lys His
      515
    <210> 3
     <211> 33
     <212> DNA
     <213> Arabidopsis thaliana
     <220>
     <221> CDS
     <222> (1) ... (33)
     <400> 3
ctc ggt aat gca gca aca gca atg cgt cca ctt
                                                               33
Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
1
              5
     <210> 4
     <211> 11
     <212> PRT
     <213> Arabidopsis thaliana
     <400> 4
Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
              5
                                1.0
     <210> 5
```

```
<211> 33
      <212> DNA
      <213> Arabidopsis thaliana
      <220>
      <221> CDS
      <222> (1)...(33)
      <400> 5
ctc ggt aat gca gga ata gca atg cgt cca ctt
                                                                       \33
 Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
      <210> 6
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
      <400> 6
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
      <210> 7
      <211> 33
      <212> DNA
      <213> Arabidopsis thaliana
      <220>
      <221> CDS
      <222> (1)...(33)
      <400> 7
ctc ggt aat gca gca ata gca atg cgt cca ctt
                                                                       33
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
      <210> 8
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
      <400> 8
 Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
                                    10
      <210> 9
       <211> 33
       <212> DNA
       <213> Arabidopsis thaliana
       <220>
       <221> CDS
       <222> (1)...(33)
       <400> 9
```

```
33
ctc ggt aat gca gga ata gca atg cgt tca ctt
Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
      <210> 10
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
      <400> 10
Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
      <210> 11
      <211> 33
      <212> DNA
      <213> Arabidopsis thaliana
      <220>
      <221> CDS
      <222> (1) ... (33)
      <400> 11
ctc ggt aat gca gca aca gca atg cgt tca ctt
                                                                       33
Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
      <210> 12
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
     <400> 12
Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
      <210> 13
      <211> 33
      <212> DNA
      <213> Arabidopsis thaliana
      <220>
      <221> CDS
      <222> (1)...(33)
      <400> 13
ctc ggt aat gca gca ata gca atg cgt tca ctt
                                                                       33
Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
                 5
                                     10
      <210> 14
      <211> 11
      <212> PRT
```

<213> Arabidopsis thaliana

```
<400> 14
Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
     <210> 15
     <211> 33
     <212> DNA
     <213> Arabidopsis thaliana
     <220>
     <221> CDS
     <222> (1) ... (33)
     <400> 15
ctc ggt aat gca gga gta gca atg cgt tca ctt
                                                                      33
Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
                - 5
     <210> 16
     <211> 11
     <212> PRT
     <213> Arabidopsis thaliana
     <400> 16
Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
     <210> 17
     <211> 33
     <212> DNA
     <213> Arabidopsis thaliana
     <220>
     <221> CDS
     <222> (1)...(33)
     <400> 17
                                                                       33
ctc ggt aat gca gga tta gca atg cgt tca ctt
Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
     <210> 18
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
     <400> 18
Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
                                    1.0
      <210> 19
      <211> 33
      <212> DNA
      <213> Arabidopsis thaliana
      <220>
```

```
<221> CDS
      <222> (1)...(33)
      <400> 19
                                                                      33
ctc ggt aat gca gca gta gca atg cgt cca ctt
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
      <210> 20
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
     <400> 20
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
     <210> 21
      <211> 33
      <212> DNA
      <213> Arabidopsis thaliana
     <220>
      <221> CDS
     <222> (1)...(33)
     <400> 21
ctc ggt aat gca gca tta gca atg cgt cca ctt
                                                                      33
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
     <210> 22
      <211> 11
      <212> PRT
      <213> Arabidopsis thaliana
      <400> 22
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
      <210> 23
      <211> 3831
      <212> DNA
      <213> Brassisca napus
      <220>
      <221> modified base
      <222> 1...3831
      <223> n=a, c, g, or t
agatottaaa qqctcttttc cagtotcacc taccaaaact ataagaaaat ccacttgctg
                                                                       60
totgaaatag cogacgtgga taaagtactt aagacgtggc acattattat tggctactag
                                                                       120
aaaaaaaact catacaccat cgtaggagtt ggggttggtg aagaatttga tgggtgcctc
                                                                      180
tecececec acteaccaaa eteatgitet tigtaaagee gicactacaa caacaaagga
                                                                      240
gacgacagtt ctatagaaaa gctttcaaat tcaatcaatg gcgcaatcta gcagaatctg
                                                                      300
```

```
ccatggcgtg cagaacccat gtgttatcat ctccaatctc tccaaatcca accaaaacaa
                                                                       360
 atcacctttc tecqtetect tqaaqaegca teageetega gettettegt ggggattgaa
                                                                       420
 gaagagtgga acgatgctaa acggttctgt aattcgcccg gttaaggtaa cagcttctgt
                                                                       480
 ttccacgtcc gagaaagctt cagagattgt gcttcaacca atcagagaaa tctcgggtct
                                                                       540
                                                                       600
 cattaageta ceeggateca aatetetete caateggate eteettettg cegetetate
                                                                       660
 tgaggtacat atacttgctt agtgttaggc ctttgctgtg agattttggg aactatagac
 aatttagtaa qaatttatat ataatttttt taaaaaaaat cagaagccta tatatattta
                                                                       720
 aatttttcca aaatttttgg aggttatagg cttatgttac accattctag tctgcatctt
                                                                       780
 toggtttgag actgaagaat tttattttt aaaaaattat tatagggaac tactgtagtg
                                                                       840
 gacaacttgt tgaacagtga tgacatcaac tacatgcttg atgcgttgaa gaagctgggg
                                                                       900
                                                                       960
 cttaacgtgg aacgtgacag tgtaaacaac cgtgcggttg ttgaaggatg cggtggaata
                                                                      1020
 ttcccaqctt ccttaqattc caaqaqtgat attgagttgt accttgggaa tgcaggaaca
 gccatgcgtc cactcaccgc tgcagttaca gctgcaggtg gcaacgcgag gtaaggttaa
 cgagtttttt gttattgtca agaaattgat cttgtgtttg atgcttttag tttggtttgt
                                                                      1140
                                                                      1200
 tttctagtta tgtacttgat ggggtgccta gaatgaggga aagacctata ggagatttgg
 ttqttqqtct taagcaqctt ggtgctgatg ttgagtgtac tcttggcact aactgtcctc
                                                                      1260
 ctgttcgtgt caatgctaat ggtggccttc ccggtggaaa ggtgatcttc acatttactc
                                                                      1320
                                                                      1380
 tatgaattgt ttgcagcagt ctttgttcat cacagccttt gcttcacatt atttcatctt
 ttagtttgtt gttatattac ttgatggatc tttaaaaaagg aattgggtct ggtgtgaaag
                                                                      1440
                                                                      1500
 tgattagcaa tetttetega tteettgeag ggeegtggge attactaagt gaaacattag
 cctattaacc cccaaaattt ttgaaaaaaa tttagtatat ggccccaaaa tagttttta
                                                                      1560
                                                                      1620
 aaaaattaqa aaaactttta ataaatcgtc tacagtcccn naaatcttag agccggccct
 gettgtatgg tttctcgatt gatatattag actatgtttt gaattttcag gtgaagettt
                                                                      1680
 etggategat cagtagteag tacttgactg coetecteat ggeageteet ttagetettg
                                                                      1740
 gagacgtgga gattgagatc attgataaac tgatatctgt tccatatgtt gaaatgacat
                                                                      1800
 tgaagttgat ggagcgtttt ggtgttagtg ccgagcatag tgatagctgg gatcgtttct
                                                                      1860
                                                                      1920
 ttgtcaaggg cggtcagaaa tacaagtaat gagttctttt aagttgagag ttagattgaa
                                                                      1980
gaatgaatga ctgattaacc aaatggcaaa actgattcag gtcgcctggt aatgcttatg
tagaaggtga tgcttctagt gctagctatt tcttggctgg tgctgccatt actggtgaaa
                                                                      2040
ctqttactqt cqaaqqttqt qqaacaacta qcctccaggt agtttatcca ctctgaatca
                                                                      2160
tcaaatatta ttctccctcc gttttatgtt aagtgtcatt agcttttaaa ttttgtttca
ttaaaagtgt cattttacat tttcaatgca tatattaaat aaattttcca gtttttacta
                                                                      2220
atteattaat tageaaaate aaacaaaaat tatattaaat aatgtaaaat tegtaatttg
                                                                      2280
tgtgcaaata ccttaaacct tatgaaacgg aaaccttatg aaacagaggg agtactaatt
                                                                      2340
                                                                      2400
ttataataaa atttgattag ttcaaagttg tgtataacat gttttgtaag aatctaagct
 cattetett ttattttttg tgatgaatee aaagggagat gtgaaatteg cagaggttet
                                                                      2460
                                                                      2520
 tgagaaaatg ggatgtaaag tgtcatggac agagaacagt gtgactgtga ctggaccatc
 aagagatget tttggaatga ggcacttgeg tgetgttgat gteaacatga acaaaatgee
                                                                      2580
 tgatgtagcc atgactctag ccgttgttgc tctctttgcc gatggtccaa ccaccatcag
                                                                      2640
                                                                      2700
 agatggtaaa gcaaaaccct ctctttgaat cagcgtgttt taaaagattc atggttgctt
 aaactctatt tggtcaatgt agtggctagc tggagagtta aggagacaga gaggatgatt
                                                                      2760
 gccatttgca cagagettag aaaggtaagt tteettttet eteatgetet eteattegaa
                                                                      2820
 gttaatcgtt gcataacttt ttgcggtttt tttttttgcg ttcagcttgg agctacagtg
                                                                      2880
                                                                      2940
 gaagaaggtt cagattattg tgtgataact ccaccagcaa aggtgaaacc ggcggagatt
 gatacgtatg atgatcatag aatggcgatg gcgttctcgc ttgcagcttg tgctgatgtt
                                                                      3000
                                                                      3060
 ccaqtcacca tcaaqqatcc tggctgcacc aggaagactt tccctgacta cttccaagtc
                                                                      3120
 cttgaaagta tcacaaagca ttaaaagacc ctttcctctg atccaaatgt gagaatctgt
                                                                      3180
 tgctttctct ttgttgccac tgtaacattt attagaagaa caaagtgtgt gtgttaagag
                                                                      3240
 tqtqtttgct tqtaatgaac tgagtgagat gcaatcgttg aatcagtttt gggccttaat
 aaagggttta ggaagctgca gcgagatgat tgtttttgat cgatcatctt tgaaaatgtg
                                                                      3300
 tttqtttqaq taatttttct aqqqttqaqt tqattacact aagaaacact ttttgatttt
                                                                      3360
                                                                      3420
 ctattacacc tataqacact tettacatgt gacacacttt gttgttggca agcaacagat
 tqtqqacaat tttgccttta atggaaagaa cacagttgtg gatgggtgat ttgtggacga
                                                                      3480
 ttccatgtgt ggttagggtg atttgtggac ggatgatgtg tagatgagtg atgagtaatg
                                                                      3540
 tgtgaatatg tgatgttaat gtgtttatag tagataagtg gacaaactct ctgttttgat
                                                                      3600
 tccataaaac tatacaacaa tacgtggaca tggactcatg ttactaaaat tataccgtaa
                                                                      3660
 aacgtggaca cggactctgt atctccaata caaacacttg gcttcttcag ctcaattgat
                                                                       3720
 aaattatotg cagttaaact toaatcaaga tgagaaagag atgatattgt gaatatgago
                                                                      3780
```

```
<210> 24
<211> 1944
<212> DNA
```

<213> Petunia hybrida

<400> 24

```
gaattccctc aatctttact ttcaagaatg gcacaaatta acaacatggc tcaagggata
                                                                       60
 caaaccctta atcccaattc caatttccat aaaccccaaq ttcctaaatc ttcaagtttt
                                                                      120
 cttqtttttq qatctaaaaa actqaaaaat tcaqcaaatt ctatqttqgt tttgaaaaaa
                                                                      180
 gattcaattt ttatqcaaaa qttttqttcc tttaggattt cagcatcagt ggctacagca
                                                                      240
 cagaageett etgagatagt gttgcaacce attaaagaga tttcaggcac tgttaaattg
                                                                      300
                                                                      360
 cctqqctcta aatcattatc taataqaatt ctccttcttg ctgccttatc tgaaggaaca
 actgtggttg acaatttact aagtagtgat gatattcatt acatgcttgg tgccttgaaa
                                                                      420
 acacttggac tgcatgtaga agaagatagt gcaaaccaac gagctgttgt tgaaggttgt
                                                                      480
 ggtgggcttt tccctgttgg taaagagtcc aaggaagaaa ttcaactgtt ccttggaaat
 qcaqqaacaq caatqcggcc actaacagca gcagttactg tagctggtgg aaattcaagg
                                                                      600
 tatgtacttg atggagttcc tcgaatgaga gagagaccaa ttagtgattt ggttgatggt
                                                                      660
 cttaaacagc ttggtgcaga ggttgattgt ttccttggta cgaaatgtcc tcctgttcga
                                                                      720
                                                                      780
 attqtcaqca aqqqaqqtct tcctqqaqqq aaggtcaagc tctctggatc cattagcagc
                                                                      840
 caatacttqa ctqctctqct tatgqctqct ccactgqctt taggagatqt ggagattgaa
                                                                      900
 atcattgaca aactaattag tgtaccttat gtcgagatga cattgaagtt gatggagcga
 tttqqtattt ctqtqqaqca cagtagtagc tgggacaggt tctttqtccg aggaggtcag
                                                                      960
 aaatacaagt ctcctggaaa agcttttgtc gaaggtgatg cttcaagtgc tagctacttc
                                                                     1020
 ttggctggtg cagcagtcac aggtggaact atcactgttg aaggttgtgg gacaaacagt
                                                                     1080
 ttacaggggg atgtcaaatt tgctgaggta cttgaaaaaa tgggagctga agttacgtgg
                                                                     1140
 acagagaaca gtgtcacagt caaaggacct ccaaggagtt cttctgggag gaagcatttg
                                                                     1200
cgtgccattg atgtgaacat gaataaaatg cctgatgttg ccatgacact tgctgttgtt
                                                                     1260
qcactttatq ctqatqqtcc cacaqctata aqaqatqttq ctagctqqag agtcaaggaa
                                                                     1320
                                                                     1380
actqaqcqca tqatcqccat atqcacagaa cttaggaagt taggagcaac cgttgaagaa
ggaccagact actgcataat caccccaccg gagaaactaa atgtgaccga tattgataca
                                                                     1440
tacgatgatc acaggatggc catggctttt tetettgetg ettgtgcaga tgttcccgtc
                                                                     1500
 accatcaatg accotggctg cacgoggaaa accttocota actactttga tgtacttcag
                                                                     1560
                                                                     1620
caqtactcca aqcattqaac cqcttcccta tattgcagaa tgtaagtaag aatatgtgaa
qaqtttaqtt cttqtacaaq acaggotacg actgootggt atcagaacca caatgggtto
                                                                     1680
 catttcagtt cagaagggca ttccaaggct tcgaactctt tacttatttg cgagtgatga
                                                                     1740
 aatgtatttg ttagagttga gettettttt gtetttaagg aatgtaeact aatagagtta
                                                                     1800
 agaattacta gtatgggcca gtgtaaggag tactattact ctttgcttat tttattgatt
                                                                     1860
 gagttttgtc aaggatctgg ctttgtcaag aattactggt taattttatt gacaatctca
                                                                     1920
 tgtgtctaaa tgaaattgtt tgat
                                                                     1944
```

<210> 25 <211> 1335 <212> DNA

<213> Zea mays

<400> 25

gegggtgeeg aggagategt getgeageee ateaaggaga teteeggeae egteaagetg 60 120 coggggtcca agtogottto caacoggato otootactog cogecotgto cgaggggaca acaqtqgttg ataacctgct gaacagtgag gatgtccact acatgctcgg ggccttgagg 180 actettggtc tetetgtega ageggacaaa getgecaaaa gagetgtagt tgttggetgt 240 300 ggtggaaagt teccagttga ggatgetaaa gaggaagtge agetettett ggggaatget 360 qqaactqcaa tqcgqccatt gacagcagct gttactgctg ctggtggaaa tgcaacttac 420 gtgcttgatg gagtaccaag aatgagggag agacccattg gcgacttggt tgtcggattg aagcagettg gtgcagatgt tgattgttte ettggcactg actgeceace tgttegtgte 480 aatggaateg gagggctacc tggtggcaag gtcaagetgt ctggetecat cagcagtcag 540 tacttgagtg cottgctgat ggctgctcct ttggctcttg gggatgtgga gattgaaatc 600

attgataaat taatctccat tccgtacgtc gaaatgacat tgagattgat ggagcgtttt 660 ggtgtgaaag cagagcattc tgatagctgg gacagattct acattaaggg aggtcaaaaa 720 tacaagtccc ctaaaaatgc ctatgttgaa ggtgatgcct caagcgcaag ctatttcttg 780 gctggtgctg caattactgg agggactgtg actgtggaag gttgtggcac caccagtttg 840 caqqqtgatg tgaagtttgc tgaggtactg gagatgatgg gagcgaaggt tacatggacc 900 gagactageg taactgttac tggcccaceg egggagecat ttgggaggaa acacetcaag 960 gcgattgatg tcaacatgaa caagatgcct gatgtcgcca tgactcttgc tgtggttgcc ctetttgeeg atggeeegae ageeateaga gaegtggett cetggagagt aaaggagaee gagaggatgg ttgcgatccg gacggagcta accaagctgg gagcatctgt tgaggaaggg 1140 coggactact gcatcatcac gccgccggag aagctqaacq tgacqqcqat cgacacqtac gacgaccaca ggatggccat ggccttctcc cttgccgcct gtgccgaggt ccccgtcacc 1260 atcogggacc ctgggtgcac ccggaagacc ttccccgact acttcgatgt gctgagcact 1320 ttcgtcaaga attaa

<210> 26

<211> 516 <212> PRT

<213> Brassisca napus

<400> 26

Met Ala Gln Ser Ser Arg Ile Cys His Gly Val Gln Asn Pro Cys Val Ile Ile Ser Asn Leu Ser Lys Ser Asn Gln Asn Lys Ser Pro Phe Ser Val Ser Leu Lys Thr His Gln Pro Arg Ala Ser Ser Trp Gly Leu Lys 45 Lys Ser Gly Thr Met Leu Asn Gly Ser Val Ile Arg Pro Val Lys Val 55 Thr Ala Ser Val Ser Thr Ser Glu Lys Ala Ser Glu Ile Val Leu Gln 70 75 Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro Gly Ser Lys Ser 85 90 Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr 100 105 Val Val Asp Asn Leu Leu Asn Ser Asp Asp Ile Asn Tyr Met Leu Asp 115 120 Ala Leu Lys Lys Leu Gly Leu Asn Val Glu Arg Asp Ser Val Asn Asn 130 135 140 Arg Ala Val Val Glu Gly Cys Gly Gly Ile Phe Pro Ala Ser Leu Asp 150 155 Ser Lys Ser Asp Ile Glu Leu Tyr Leu Gly Asn Ala Gly Thr Ala Met 170 Arg Pro Leu Thr Ala Ala Val Thr Ala Ala Gly Gly Asn Ala Ser Tyr 185 Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro Ile Gly Asp Leu 200 Val Val Gly Leu Lys Gln Leu Gly Ala Asp Val Glu Cys Thr Leu Gly 215 Thr Asn Cys Pro Pro Val Arg Val Asn Ala Asn Gly Gly Leu Pro Gly 230 240 Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln Tyr Leu Thr Ala 245 255 Leu Leu Met Ala Ala Pro Leu Ala Leu Gly Asp Val Glu Ile Glu Ile 260 265 Ile Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met Thr Leu Lys Leu 275 280 285 Met Glu Arg Phe Gly Val Ser Ala Glu His Ser Asp Ser Trp Asp Arg 290 295

Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly Pro Ser Arg Asp Ala Phe Gly Met Arg His Leu Arg Ala Val Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro Pro Ala Lys Val Lys Pro Ala Glu Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Lys Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln Val Leu Glu Ser Ile Thr Lys His

<210> 27 <211> 516 <212> PRT

<213> Petunia hybrida

<400> 27

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile Ser Ala Ser Val Ala Thr Ala Gln Lys Pro Ser Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser 9.0 Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Ser Ser Asp Asp Ile His Tyr Met Leu Gly Ala Leu Lys Thr Leu Gly Leu His Val Glu Glu Asp Ser Ala Asn Gln Arg Ala Val Val Glu Gly Cys Gly Gly Leu Phe Pro Val Gly Lys Glu Ser Lys Glu Glu Ile Gln Leu Phe Leu Gly Asn Ala Gly Thr Ala Met

```
Arg Pro Leu Thr Ala Ala Val Thr Val Ala Gly Gly Asn Ser Arg Tyr
                            185
Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro Ile Ser Asp Leu
                        200
       195
Val Asp Gly Leu Lys Gln Leu Gly Ala Glu Val Asp Cys Phe Leu Gly
                    215
                                      220
Thr Lys Cys Pro Pro Val Arg Ile Val Ser Lys Gly Gly Leu Pro Gly
                230
                                  235
Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln Tyr Leu Thr Ala
                               250
             245
Leu Leu Met Ala Ala Pro Leu Ala Leu Gly Asp Val Glu Ile Glu Ile
          260
                           265
Ile Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met Thr Leu Lys Leu
                        280
Met Glu Arg Phe Gly Ile Ser Val Glu His Ser Ser Ser Trp Asp Arg
                    295
                                      300
Phe Phe Val Arg Gly Gly Gln Lys Tyr Lys Ser Pro Gly Lys Ala Phe
                 310
                                   315
Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala
              325
                               330
Val Thr Gly Gly Thr Ile Thr Val Glu Gly Cys Gly Thr Asn Ser Leu
          340
                            345
Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Ala Glu
       355
                       360
                                         365
Val Thr Trp Thr Glu Asn Ser Val Thr Val Lys Gly Pro Pro Arg Ser
                    375
Ser Ser Gly Arg Lys His Leu Arg Ala Ile Asp Val Asn Met Asn Lys
385
               390
                                   395
Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Tyr Ala Asp
            405
                             410
Gly Pro Thr Ala Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr
       420 425
Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr
    435 440 445
Val Glu Glu Gly Pro Asp Tyr Cys Ile Ile Thr Pro Pro Glu Lys Leu
                    455 460
Asn Val Thr Asp Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala
                470 475
Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Asn Asp Pro
            485
                   490 495
Gly Cys Thr Arg Lys Thr Phe Pro Asn Tyr Phe Asp Val Leu Gln Gln
          500
                 505
Tyr Ser Lys His
      515
     <210> 28
     <211> 444
     <212> PRT
     <213> Zea mavs
```

Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu 5.5 Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Gly Cys 7.0 75 Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe 85 90 Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr 105 100 Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met 115 120 Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly 135 140 Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val 155 150 Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser 165 170 Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu Ala 180 185 190 Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Ile Pro 195 200 205 Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala 210 215 220 Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys 230 235 Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala 245 250 Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val 260 265 Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu 275 280 285 Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val 290 295 300 Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys 310 315 Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu 325 330 Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val 340 345 350 Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr 355 360 365 Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys 370 375 380 Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr 390 395 Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu 405 410 415 Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro 420 425 Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn 440

<210> 29

<211> 64 <212> DNA

<213> Artificial Sequence

<220>

<223> Mutant primer

	<400>	29				
cattte	acc t	geageagtg accgcagegg	taaqtqqacq	cattgctgtt	getgeattac	60
cgag		3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	3 33 3	5 5		64
cgug						
	010	2.0				
	:210>					
	:211>					
	<212>					
	<213>	Artificial Sequence				
	:220>					
		Mutant primer				
,	.2237	nacane primer				
		3.0				
	<400>					60
	cacc t	gcagcagtg accgcagcgg	taagtggacg	cattgctatt	getgeattae	
cgag						64
	<210>	31				
	<211>	64				
	<212>					
		Artificial Sequence				
	.2132	Arciriciar Sequence				
	<220>					
	<223>	Mutant primer				
	<400>	31				
catttc	cacc t	gcagcagtg accgcagcgg	taaqtqaacq	cattqctatt	cctgcattac	60
cgag		, , , , , , , ,		-	-	64
-5-5						
	<210>	3.2				
	<211>					
	<212>					
	<213>	Artificial Sequence				
	<220>					
	<223>	Mutant primer				
		-				
	<400>	32				
		gcagcagtg accgcagcgg	taaataaaaa	cattactatt	actacattac	60
	Jacc C	geageageg acegeagegg	caugegaacg	carrageogee	googoaccao	64
cgag						0.1
	<210>					
	<211>					
	<212>					
	<213>	Artificial Sequence				
		-				
	<220>					
		Mutant primer				
	~~~	acane primer				
	. 4 0 0 .	2.2				
	<400>					
	cacc t	gcagcagtg accgcagcgg	taagtgaacg	cattgctatt	gutgeattae	60
cgag						64
	<210>	34				
	<211>	64				
	<212>					
		Artificial Sequence				
	~~~~	bequence				
	. 220					
	<220>					

<223> Mutant primer	
<400> 34 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctgtt attgcattac cgag	60 64
<210> 35 <211> 64 <212> DNA <213> Artificial Sequence	
<220> <223> Mutant primer	
<400> 35 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctact cctgcattac cgag	60 64
<210> 36 <211> 64 <212> DNA <213> Artificial Sequence	
<220> <223> Mutant primer	
<400> 36 egtttecaec tgeageagtg acegeagegg taagtgaaeg cattgetaat cetgeattae egag	60 64
<210> 37 <211> 64 <212> DNA <213> Artificial Sequence	
<220> <223> Mutant primer	
<400> 37 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctact gctgcattac cgag	60 64
<210> 38 <211> 64 <212> DNA <213> Artificial Sequence	
<220> <223> Mutant primer	
<400> 38 egtttecace tgcagcagtg accgcagcgg taagtggacg cattgctaat gctgcattac cgag	60 64
<210> 39 <211> 5 <212> PRT <213> Petunia hybrida	

```
<400> 39
 Leu Phe Leu Gly Asn
       <210> 40
       <211> 30
       <212> DNA
       <213> Artificial Sequence
       <220>
       <223> Primer
       <400> 40
                                                                         30
 gctctagaga aagcgtcgga gattgtactt
       <210> 41
       <211> 41
       <212> DNA
       <213> Artificial Sequence
       <220>
       <223> Primer
       <400> 41
gcagatotga gotottagtg otttgtgatt otttcaagta o
                                                                         41
      <210> 42
       <211> 28
       <212> DNA
       <213> Artificial Sequence
       <220>
       <223> Primer
      <400> 42
                                                                         28
gegtetagaa aaacgagata aggtgcag
       <210> 43
       <211> 38
       <212> DNA
       <213> Artificial Sequence
       <220>
       <223> Primer
       <400> 43
 geggateete aggatttttt egaaagetta tttaaatg
                                                                         38
       <210> 44
       <211> 20
       <212> DNA
       <213> Artificial Sequence
       <220>
       <223> Primer
       <400> 44
                                                                         20
 gaaagcgtcg gagattgtac
```